Nitrogen-containing functional group-substituted pyridazinopyridone derivative and use thereof
By developing nitrogen-containing functional groups-substituted pyridazinopyridone derivatives, the problem of poor effectiveness of existing SOS1 inhibitors has been solved, effective inhibition of SOS1 has been achieved, cancer treatment potential has been improved, and the drug properties of the compounds have been improved. Oral bioavailability.
Patent Information
- Application Number
- PCT/CN2024/096254
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-05
AI Technical Summary
Existing SOS1 target drugs have not met the clinical meeting needs, and there is a lack of effective SOS1 inhibitors, especially in the treatment of SOS1-mediated cancers and other diseases.
A class of nitrogen-containing functional group-substituted pyridazinopyridone derivatives have been developed as a powerful inhibitor of SOS1. The inhibitory activity and drug properties of SOS1 are improved through specific compound structure design and synthesis methods.
This compound significantly improves the inhibitory activity of SOS1, enhances the therapeutic potential for cancer and other diseases, has better liver microsomal metabolic stability and oral bioavailability, reduces the inhibitory effect of liver drug metabolic enzymes, and provides Better properties of the medicine.
Smart Images

Figure PCTCN2024096254-FTAPPB-I100001 
Figure PCTCN2024096254-FTAPPB-I100002 
Figure PCTCN2024096254-FTAPPB-I100003
Abstract
Description
Nitrogen-containing functional group-substituted pyridazinone derivatives and uses thereof Technical Field
[0001] The present invention relates to the field of medical technology, in particular to a class of nitrogen-containing functional group-substituted pyridazinopyridone derivatives used as SOS1 protein inhibitors and uses thereof. Background Art
[0002] SOS1 (son of sevenless homolog 1) protein is a regulatory protein widely expressed in cells. As a type of guanine nucleotide exchange factor for Ras or Rac1 protein, it plays an important regulatory role in the intracellular Ras or Rac1 signal transduction pathway (Baltanás, FC; Zarich, N.; JM; Santos, E. Biochim. Biophys. Acta. Rev. Cancer. 2020, 1874, 188445). The role of SOS1 protein in the Ras signal transduction pathway is to promote the release of GDP from Ras and bind to GTP, thereby converting the Ras protein from an inactive state to an active state.
[0003] There are three genes in the RAS family known to date: KRAS, NRAS, and HRAS. Mutations in RAS enzymes are closely associated with tumorigenesis, with mutations detected in approximately 25% of all tumors (de Castro J.; Belda-Iniesta C.; Transl Lung Cancer Res. 2013, 2(2), 142-51.), RAS mutation types vary in different tumor types. RAS mutations (KRAS, NRAS, HRAS) are present in 90% of pancreatic cancers, 45% of colon cancers, and 35% of lung cancers. Non-small cell lung cancer (NSCLC) accounts for 80% of all lung cancer cases (Jemal, B.; et al, CA Cancer J. Clin. 2011, 61(2), 69-90), and Ras proto-oncogene is the most commonly mutated gene in NSCLC (Prior, L. et al, Cancer Res. 2012, 72(10), 2457-2467; Li, L. et al, J Exp Clin Cancer Res. 2018, 37(1), 178), among which v-Ki-ras2Kirsten rat sarcoma viral oncogene (Kras) accounts for 90% of RAS mutations in lung adenocarcinoma (Hunter, JC; et al, Mol. Cancer Res. 2015, 13(9), 1325-35).
[0004] As the "pacemaker" of Kras, SOS1 plays an important regulatory role in many signal transduction pathways in cells. Studies have shown that inhibiting SOS1 activity has an effective inhibitory effect on the proliferation of cancer cells caused by all major Kras gene mutations (Kessler, D.; Gerlach, D.; Kraut, N.; McConnell, DB Curr. Opin. Chem. Biol. 2021, 62, 109-118). In addition, a clinical study in 62 patients with ovarian cancer showed that RAS mutations and SOS1 mutations were significantly increased in ovarian cancer tissues, and were associated with a shortened PFS in patients with prognosis, suggesting that RAS and SOS1 targeted therapy has potential value in patients with ovarian cancer. At the same time, SOS1 gene mutations have also been found in many other cancer cells, such as embryonal rhabdomyosarcoma, Sertoli cell testicular tumors, cutaneous granulosa cell tumors (Denayer, et al., Genes Chromosomes Cancer, 2010, 49(3):242-52) and lung adenocarcinoma (Cancer Genome Atlas Research Network, Nature, 2014, 511(7511), 543-50). In addition, studies have found that the SOS1 gene is highly expressed in bladder cancer (Watanabe, et al., IUBMB Life., 2000, 49(4), 317-20) and prostate cancer (Timofeeva, et al., Int. J. Oncol., 2009, 35(4):751-60). In the development and progression of chronic myeloid leukemia, BCR-ABL activates GRB2 by phosphorylation and recruits SOS1, thereby continuously activating the Ras / MAPK signaling pathway, leading to the malignant proliferation of hematopoietic stem cells. Therefore, SOS1 protein is also a potential new target for the treatment of chronic myeloid leukemia. In addition to cancer, studies have shown that hereditary SOS1 gene mutations are also closely related to some pathogenic rash diseases such as Noonan syndrome (NS), cardiofacial cutaneous syndrome (CFC) and hereditary gingival fibromatosis type I (Pierre, et al., Biochem. Pharmacol., 2011, 82(9):1049-56).
[0005] SOS1 inhibition is mechanistically similar to SHP2 inhibition (Nichols, RJ; et al. Nat Cell Biol. 2018, 20(9), 1064-1073), suggesting that SOS1 inhibition can also enhance KRAS G12CPreliminary data show that there is a significant synergistic effect between SOS1 and MEK inhibition in multiple PDX models with G12 and G13 KRAS mutations (Hofmann, MH; et al, Cancer Discov. 2020, 10.1158 / 2159-8290.CD-20-0142.). In addition to inhibiting Kras wt In addition to feedback activation of KRAS G12C Allosteric inhibitors can only bind to KRAS GDP Inhibition of SOS1 by increasing mutant KRAS G12C to directly increase the number of KRAS G12C The potential advantage of the efficacy of inhibitors (Hillig, RC; et al, Proc. Nat. Acad. Sci. USA. 2019, 116(7), 2551-2560). Although further research is needed, as a combination therapy strategy, inhibition of SOS1 has great potential for clinical application.
[0006] Currently, there are still no drugs targeting the SOS1 target on the market worldwide, and the compounds under development are all in the early clinical or preclinical research stage. Although a few pharmaceutical research companies or research institutions have conducted corresponding research on SOS1 inhibitors and have published relevant patents, such as Boehringer Ingelheim's disclosure of a class of benzylamine-substituted quinazoline derivatives as SOS1 inhibitors (US20190358230A1) and Bayer Pharmaceuticals' disclosure of a class of 2-methyl-azaquinazoline compounds as SOS1 inhibitors (WO2019201848A1), the SOS1 inhibitors currently developed are far from meeting clinical needs, and the development of new SOS1 inhibitors still has very broad clinical application prospects.
[0007] Summary of the Invention
[0008] The main technical problem solved by the present invention is to provide a class of pyridazine-pyridone derivatives substituted with nitrogen-containing functional groups, which have a strong inhibitory effect on SOS1.
[0009] To solve the above technical problems, the present invention provides a compound represented by Formula I, or its tautomers, stereoisomers, solvates, metabolites, isotope-labeled substances, pharmaceutically acceptable salts, and cocrystals:
[0010] in:
[0011] Ring A is selected from aryl, heteroaryl, wherein the aryl, heteroaryl is optionally selected from halogen, alkyl, alkoxy, -OH, -CN, -NR5R6, -SF5, -SO2R 10The alkyl and alkoxy groups may be further substituted by substituents selected from halogen, -NR5R6, and -OH, wherein R5 and R6 are independently selected from H, alkyl, R 10 is an alkyl group and is optionally substituted by halogen; or, two substituents on the aryl or heteroaryl group are linked to form an aliphatic carbocyclic ring, and the aliphatic carbocyclic ring is optionally substituted by halogen;
[0012] R a 、R b 、R c Independently selected from H, alkyl;
[0013] R1 and R3 are independently selected from H, halogen, alkyl, alkoxy, -OH, -CN, -NR7R8, and the alkyl and alkoxy groups are optionally substituted with substituents selected from halogen and -NR7R8, wherein R7 and R8 are independently selected from H and alkyl;
[0014] R2 is selected from H, alkyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, said cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl being optionally selected from halogen, alkyl, alkoxy, -C(=O)R9 is substituted, R9 is selected from alkyl, cycloalkyl, heterocycloalkyl;
[0015] R4 is -NR 11 R 12 , R 11 、R 12 Independently selected from H, alkyl, cycloalkyl, heterocycloalkyl, wherein, when R 11 and / or R 12 When alkyl, the alkyl group may be selected from -OH, alkenyl, halogen, -NR 14 R 15 , substituted by a cycloalkyl substituent, R 14 、R 15 Independently selected from H, alkyl; when R 11 and / or R 12 When selected from cycloalkyl and heterocycloalkyl, the cycloalkyl and heterocycloalkyl may be optionally substituted by an alkyl; or
[0016] R 11 、R 12 and the N atom connected thereto together form a heterocycloalkyl group, wherein the heterocycloalkyl group can be optionally selected from halogen, alkyl, cycloalkyl, -C(=O)R 13 、 -OH, the alkyl group may be further substituted by a substituent selected from -OH, cycloalkyl, wherein R 13 is an alkyl group; or
[0017] R11 、R 12 Together with the nitrogen atom to which it is attached, it forms a heteroaryl group.
[0018] Further, ring A is selected from aryl and heteroaryl, and the aryl and heteroaryl are optionally selected from halogen, alkyl, alkoxy, -OH, -CN, -NR5R6, -SF5, -SO2R 10 The alkyl and alkoxy groups may be further substituted by substituents selected from halogen, -NR5R6, wherein R5 and R6 are independently selected from H, alkyl, R 10 is alkyl and is optionally substituted by halogen.
[0019] Furthermore, R1 and R3 are independently selected from H, alkyl, alkoxy, -OH, -CN, -NR7R8, and the alkyl and alkoxy groups are optionally substituted by substituents selected from halogen and -NR7R8, wherein R7 and R8 are independently selected from H and alkyl.
[0020] Further, R4 is -NR 11 R 12 , where R 11 、R 12 is independently selected from H, alkyl, cycloalkyl, the alkyl group is optionally substituted with a substituent selected from -OH, alkenyl, the cycloalkyl group is optionally substituted with an alkyl group; or, R 11 、R 12 and the N atom connected thereto together form a heterocycloalkyl group, wherein the heterocycloalkyl group can be optionally selected from halogen, alkyl, cycloalkyl, -C(=O)R 13 、 Substituents, R 13 is an alkyl group; or, R 11 、R 12 Together with the nitrogen atom to which it is attached, it forms a heteroaryl group.
[0021] Alternatively, the present invention provides a compound of Formula I, or a tautomer, stereoisomer, solvate, metabolite, isotope-labeled substance, pharmaceutically acceptable salt, or cocrystal thereof:
[0022] in:
[0023] Ring A is selected from aryl, heteroaryl, wherein the aryl, heteroaryl is optionally selected from halogen, alkyl, alkoxy, -OH, -CN, -NR5R6, -SF5, -SO2R 10 The alkyl and alkoxy groups may be further substituted by substituents selected from halogen, -NR5R6, wherein R5 and R6 are independently selected from H, alkyl, R 10 is alkyl and is optionally substituted with halogen;
[0024] R a 、R b 、R c Independently selected from H, alkyl;
[0025] R1 and R3 are independently selected from H, alkyl, alkoxy, -OH, -CN, -NR7R8, and the alkyl and alkoxy groups are optionally substituted with substituents selected from halogen and -NR7R8, wherein R7 and R8 are independently selected from H and alkyl;
[0026] R2 is selected from H, alkyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, said cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl being optionally selected from halogen, alkyl, alkoxy, -C(=O)R9 is substituted, R9 is selected from alkyl, cycloalkyl, heterocycloalkyl;
[0027] R4 is -NR 11 R 12 , where R 11 、R 12 is independently selected from H, alkyl, cycloalkyl, the alkyl group is optionally substituted with a substituent selected from -OH, alkenyl, the cycloalkyl group is optionally substituted with an alkyl group; or, R 11 、R 12 and the N atom connected thereto together form a heterocycloalkyl group, wherein the heterocycloalkyl group can be optionally selected from halogen, alkyl, cycloalkyl, -C(=O)R 13 、 Substituents, R 13 is an alkyl group; or, R 11 、R 12 Together with the nitrogen atom to which it is attached, it forms a heteroaryl group.
[0028] Furthermore, ring A is selected from 6-12 membered aryl groups and 5-12 membered heteroaryl groups, wherein the heteroaryl group contains a heteroatom selected from N, O, and S, and the substituents of the above groups are as defined in any of the above technical solutions.
[0029] Preferably, ring A is phenyl, and its substituents are as defined in any of the above technical solutions.
[0030] Furthermore, the substituent contained in ring A is selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, -OH, -CN, -NR5R6, -SF5, -SO2R 10 The alkyl and alkoxy groups may be further substituted by substituents selected from halogen, -NR5R6, and -OH, wherein R5 and R6 are independently selected from H, C1-C6 alkyl, and R 10is a C1-C6 alkyl group and is optionally substituted by halogen; or, two substituents on ring A are linked to form a 5-6 membered aliphatic carbocyclic ring, and the aliphatic carbocyclic ring is optionally substituted by halogen.
[0031] Preferably, the substituent contained in ring A is selected from halogen, C1-C6 alkyl, -CN, -NR5R6, -SF5, -SO2R 10 The alkyl group may be further substituted by a substituent selected from halogen and -OH, wherein R5 and R6 are independently selected from H, C1-C6 alkyl, R 10 is a C1-C6 alkyl group and is optionally substituted by halogen; or, two substituents on ring A are linked to form a 5-6 membered aliphatic carbocyclic ring, and the aliphatic carbocyclic ring is optionally substituted by halogen.
[0032] Preferably, the substituent contained in ring A is selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, -OH, -CN, -NR5R6, -SF5, -SO2R 10 The alkyl and alkoxy groups may be further substituted by a substituent selected from halogen and -NR5R6, wherein R5 and R6 are independently selected from H, C1-C6 alkyl, and R 10 It is a C1-C6 alkyl group and is optionally substituted by halogen.
[0033] Preferably, the substituent contained in ring A is selected from halogen, C1-C6 alkyl, -CN, -NR5R6, and the alkyl group is optionally further substituted by halogen, and R5 and R6 are independently selected from H and C1-C6 alkyl.
[0034] Preferably, the substituent contained in ring A is selected from -F, -CH3, -CHF2, -CF3, -CN, -NH2, -SF5, -SO2CHF2, -CF2CH2OH; or, two substituents on ring A are connected to form The ends of a and b are connected to two adjacent ring carbon atoms on ring A respectively.
[0035] Preferably, the substituent contained in ring A is selected from -F, -CH3, -CHF2, -CF3, -CN, and -NH2.
[0036] Further, Ring A is selected from:
[0037] Preferably, Ring A is selected from:
[0038] Furthermore, R a 、R b 、R c Independently selected from H, C1-C6 alkyl.
[0039] Preferably, R a 、R b 、R c Independently selected from H, methyl.
[0040] Preferably, R a is methyl, R b H, R c For H.
[0041] Furthermore, the compound structure is shown in Formula II:
[0042] Wherein each group is as defined in any of the above technical solutions.
[0043] Furthermore, R1 and R3 are independently selected from H, halogen, C1~C6 alkyl, C1~C6 alkoxy, -OH, -CN, -NR7R8, and the alkyl and alkoxy groups are optionally substituted by substituents selected from halogen and -NR7R8, wherein R7 and R8 are independently selected from H and C1~C6 alkyl.
[0044] Furthermore, R1 and R3 are independently selected from H, C1~C6 alkyl, C1~C6 alkoxy, -OH, -CN, -NR7R8, and the alkyl and alkoxy groups are optionally substituted by substituents selected from halogen and -NR7R8, wherein R7 and R8 are independently selected from H, C1~C6 alkyl.
[0045] Preferably, R1 and R3 are both H.
[0046] Further, R2 is selected from H, C1-C6 alkyl, 3-10 membered cycloalkyl, 3-10 membered heterocycloalkyl, 3-10 membered cycloalkenyl, 3-10 membered heterocycloalkenyl, and the cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl groups can be optionally selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, -C(=O)R9 is substituted by a substituent, R9 is selected from C1~C6 alkyl, 3~10 membered cycloalkyl, 3~10 membered heterocycloalkyl, and the heterocycloalkyl and heterocycloalkenyl groups contain heteroatoms selected from N, O, and S.
[0047] Preferably, R2 is selected from H, C1-C6 alkyl, 3-10 membered cycloalkyl, 3-10 membered heterocycloalkyl, 3-10 membered heterocycloalkenyl, and the cycloalkyl, heterocycloalkyl, and heterocycloalkenyl are optionally substituted by substituents selected from C1-C6 alkyl, C1-C6 alkoxy, and -C(=O)R9, and R9 is selected from C1-C6 alkyl, 3-10 membered heterocycloalkyl, and the heterocycloalkyl and heterocycloalkenyl contain 1-2 heteroatoms selected from N, O, and S.
[0048] Preferably, R2 is selected from H, C1-C6 alkyl, 3-membered cycloalkyl, 5-6-membered heterocycloalkyl, 6-membered heterocycloalkenyl, and the cycloalkyl, heterocycloalkyl, and heterocycloalkenyl are optionally substituted by substituents selected from C1-C6 alkyl, C1-C6 alkoxy, and -C(=O)R9, and R9 is selected from C1-C6 alkyl and 6-membered heterocycloalkyl, and the heterocycloalkyl and heterocycloalkenyl contain 1-2 heteroatoms selected from N and O.
[0049] Preferably, R2 is selected from C1-C6 alkyl, 3-8 membered cycloalkyl, 5-8 membered heterocycloalkyl, and the cycloalkyl and heterocycloalkyl groups are optionally substituted by substituents selected from halogen and C1-C6 alkyl, and the heterocycloalkyl group contains 1-2 heteroatoms selected from N and O.
[0050] Preferably, R2 is a C1-C6 alkyl group; or
[0051] R2 is selected from cyclopropane, cyclobutane, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, 3-azabicyclo[3.3.0]octanyl, and the above groups are optionally substituted by substituents selected from halogen and C1-C6 alkyl.
[0052] Preferably, R2 is a cyclopropane group, which is optionally substituted by a C1-C6 alkyl group.
[0053] Preferably, R2 is selected from: methyl, ethyl,
[0054] Preferably, R2 is selected from:
[0055] Further, R4 is -NR 11 R 12 , R 11 、R 12 are independently selected from H, C1-C6 alkyl, 3-10 membered cycloalkyl, 3-10 membered heterocycloalkyl, wherein the heterocycloalkyl contains a heteroatom selected from N, O, and S; wherein, when R 11 and / or R 12 When it is C1 to C6 alkyl, the alkyl group may be selected from halogen, -NR 14 R 15 , substituted by a 3- to 10-membered cycloalkyl substituent, R 14 、R 15 Independently selected from H, C1-C6 alkyl; when R 11 and / or R 12 When selected from 3- to 10-membered cycloalkyl and 3- to 10-membered heterocycloalkyl, the cycloalkyl and heterocycloalkyl may be optionally substituted by a C1-C6 alkyl.
[0056] Preferably, R4 is -NR 11R 12 , R 11 、R 12 are independently selected from H, C1-C6 alkyl, 3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1-2 heteroatoms selected from N and O; wherein, when R 11 and / or R 12 When it is C1 to C6 alkyl, the alkyl group may be selected from halogen, -NR 14 R 15 , substituted by a 3- to 8-membered cycloalkyl substituent, R 14 、R 15 Independently selected from H, C1-C6 alkyl; when R 11 and / or R 12 When selected from 3- to 8-membered cycloalkyl and 4- to 8-membered heterocycloalkyl, the cycloalkyl and heterocycloalkyl may be optionally substituted by a C1-C6 alkyl.
[0057] Preferably, R4 is -NR 11 R 12 , where R 11 、R 12 Independently selected from H, C1~C6 alkyl, 3~10-membered cycloalkyl, the C1~C6 alkyl is optionally substituted by a substituent selected from -OH, C2~C6 alkenyl, and the 3~10-membered cycloalkyl is optionally substituted by a C1~C6 alkyl.
[0058] Preferably, R4 is -NR 11 R 12 , where R 11 、R 12 Independently selected from H, C1~C6 alkyl, 3~5-membered cycloalkyl, the C1~C6 alkyl is optionally substituted by a substituent selected from -OH, C2~C6 alkenyl, and the 3~5-membered cycloalkyl is optionally substituted by a C1~C6 alkyl.
[0059] Preferably, R4 is -NR 11 R 12 , R 11 、R 12 are independently selected from H, C1-C6 alkyl, cyclopropane, bicyclo[1.1.1]pentane, oxetanyl, tetrahydropyrrolyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, 1-azabicyclo[2.2.2]octanyl; wherein, when R 11 and / or R 12 When it is C1 to C6 alkyl, the alkyl group may be selected from halogen, -NR 14 R 15 , substituted by a 3-membered cycloalkyl substituent, R 14 、R 15 Independently selected from H, C1-C6 alkyl; when R11 and / or R 12 When selected from cyclopropane, bicyclo[1.1.1]pentane, oxetanyl, tetrahydropyrrolyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, 1-azabicyclo[2.2.2]octanyl, the above groups are optionally substituted by C1-C6 alkyl.
[0060] Preferably, R4 is -NR 11 R 12 , where R 11 、R 12 Independently selected from H, methyl, ethyl, propyl, cyclopropane, wherein the cyclopropane is optionally substituted with methyl.
[0061] Preferably, R4 is selected from:
[0062] Preferably, R4 is selected from:
[0063] Preferably, R4 is
[0064] Further, R4 is -NR 11 R 12 , R 11 、R 12 and the N atom connected thereto together form a 3-10 membered heterocycloalkyl group, wherein the heterocycloalkyl group contains a heteroatom selected from N, O, and S, and the heterocycloalkyl group can be optionally selected from halogen, C1-C6 alkyl, 3-10 membered cycloalkyl, -C(=O)R 13 、 The alkyl group may be substituted by a substituent selected from -OH, a 3- to 10-membered cycloalkyl group, wherein R 13 It is a C1~C6 alkyl group.
[0065] Preferably, R4 is -NR 11 R 12 , where R 11 、R 12 and the N atom connected thereto together form a 3-10 membered heterocycloalkyl group, wherein the heterocycloalkyl group contains a heteroatom selected from N, O, and S, and the heterocycloalkyl group can be optionally selected from halogen, C1-C6 alkyl, 3-10 membered cycloalkyl, -C(=O)R 13 、 Substituents, R 13 It is a C1~C6 alkyl group.
[0066] Preferably, R4 is -NR 11 R 12 , R 11 、R12 and the nitrogen atom connected thereto together form a 4-10 membered heterocycloalkyl group, wherein the heterocycloalkyl group contains 1-2 heteroatoms selected from N, O, and S, and the heterocycloalkyl group can be optionally selected from halogen, C1-C6 alkyl, 3-5 membered cycloalkyl, -C(=O)R 13 、 -OH, the alkyl group may be further substituted by a substituent selected from -OH and a 3- to 5-membered cycloalkyl group, wherein R 13 It is a C1~C6 alkyl group.
[0067] Preferably, R4 is -NR 11 R 12 , where R 11 、R 12 and the N atom connected thereto together form a 4-6 membered heterocycloalkyl group, wherein the heterocycloalkyl group contains 1-2 heteroatoms selected from N, O, and S, and the heterocycloalkyl group can be optionally selected from halogen, C1-C6 alkyl, -C(=O)R 13 、 Substituents, R 13 It is a C1~C6 alkyl group.
[0068] Preferably, R4 is -NR 11 R 12 , R 11 、R 12 Together with the N atoms connected to it The above groups can be optionally selected from halogen, C1-C6 alkyl, 3-5 membered cycloalkyl, -C(=O)R 13 、 -OH, the alkyl group may be further substituted by a substituent selected from -OH and a 3- to 5-membered cycloalkyl group, wherein R 13 It is a C1~C6 alkyl group.
[0069] Preferably, R4 is -NR 11 R 12 , where R 11 、R 12 and the N atom connected thereto together form azetidinyl, tetrahydropyrrolyl, tetrahydrothiazolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 3-azabicyclo[3.1.0]hexane, wherein the above groups are optionally selected from fluorine, methyl, -C(=O)R 13 、 Substituents, R 13 It is a methyl group.
[0070] Preferably, R4 is -NR 11 R12 , where R 11 、R 12 Together with the N atom connected thereto, azetidinyl and piperazinyl are formed, wherein the above groups are optionally selected from fluorine, methyl, -C(=O)R 13 、 Substituents, R 13 It is a methyl group.
[0071] Preferably, R4 is selected from:
[0072] Preferably, the configuration of R4 is selected from at least one of the following:
[0073] Preferably, R4 is selected from:
[0074] Preferably, for
[0075] Further, R4 is -NR 11 R 12 , where R 11 、R 12 Together with the nitrogen atom connected thereto, they form a 5- to 10-membered heteroaryl group, wherein the heteroaryl group contains a heteroatom selected from N, O, and S.
[0076] Preferably, R4 is -NR 11 R 12 , where R 11 、R 12 Together with the nitrogen atom connected thereto, they form a 5-membered heteroaryl group, wherein the heteroaryl group contains 1 to 3 nitrogen heteroatoms.
[0077] Preferably, R4 is -NR 11 R 12 , where R 11 、R 12 Together with the nitrogen atom connected to it, it forms a pyrazolyl group, an imidazolyl group, a 1,2,3-triazolyl group, and a 1,2,4-triazolyl group.
[0078] Preferably, R4 is selected from:
[0079] Furthermore, the compound is selected from one of the following:
[0080] The present invention provides a pharmaceutical composition containing the compound, or its tautomers, stereoisomers, solvates, metabolites, isotope-labeled substances, pharmaceutically acceptable salts, cocrystals, and pharmaceutically acceptable excipients or auxiliary ingredients.
[0081] The present invention provides the use of the compound, or its tautomer, stereoisomer, solvate, metabolite, isotope-labeled product, pharmaceutically acceptable salt, cocrystal, or pharmaceutical composition in the preparation of an SOS1 inhibitor.
[0082] The present invention provides use of the compound, or its tautomer, stereoisomer, solvate, metabolite, isotope-labeled product, pharmaceutically acceptable salt, cocrystal, or pharmaceutical composition in the preparation of a medicament for treating a disease mediated by SOS1.
[0083] Furthermore, the disease is selected from: cancer, pathogenic rash disease.
[0084] Furthermore, the cancer is selected from the group consisting of non-small cell lung cancer, lung cancer, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, chronic myeloid leukemia, colorectal cancer, brain cancer, liver cancer, kidney cancer, gastric cancer, and breast cancer;
[0085] The pathogenic rash disease is selected from the group consisting of: Noonan syndrome, cardiofacial cutaneous syndrome, and hereditary gingival fibromatosis type I.
[0086] The present invention provides use of the compound, or its tautomer, stereoisomer, solvate, metabolite, isotope-labeled product, pharmaceutically acceptable salt, cocrystal, or pharmaceutical composition in the preparation of a drug for treating a disease causing overexpression of SOS1 protein.
[0087] The present invention provides the use of the compound, or its tautomer, stereoisomer, solvate, metabolite, isotope-labeled product, pharmaceutically acceptable salt, cocrystal, or pharmaceutical composition in the preparation of a drug for treating diseases caused by overexpression of SOS1 protein.
[0088] The present invention provides a method for inhibiting SOS1, comprising administering an effective amount of the compound, or its tautomer, stereoisomer, solvate, metabolite, isotope-labeled substance, pharmaceutically acceptable salt, cocrystal, or pharmaceutical composition.
[0089] The present invention provides a method for treating a disease mediated by SOS1, comprising administering a therapeutically effective amount of the compound, or its tautomer, stereoisomer, solvate, metabolite, isotope-labeled form, pharmaceutically acceptable salt, cocrystal, or pharmaceutical composition.
[0090] The present invention provides a method for treating a disease resulting in overexpression of SOS1 protein, comprising administering a therapeutically effective amount of the compound, or its tautomer, stereoisomer, solvate, metabolite, isotope-labeled form, pharmaceutically acceptable salt, cocrystal, or pharmaceutical composition.
[0091] The present invention provides a method for treating diseases caused by overexpression of SOS1 protein, comprising administering a therapeutically effective amount of the compound, or its tautomer, stereoisomer, solvate, metabolite, isotope label, pharmaceutically acceptable salt, cocrystal, or pharmaceutical composition.
[0092] Definition of terms:
[0093] The "tautomers" mentioned in the present invention refer to functional group isomers produced by the movement of an atom in a molecule between two positions, especially when there is a mobile hydrogen atom in the molecule, such as keto and enol tautomers.
[0094] As used herein, "stereoisomers" refer to isomers resulting from molecules in which the atoms or atomic groups have the same order of interconnection but different spatial arrangements, including cis-trans isomers, optical isomers, and conformational isomers. Stereoisomers herein also include mixtures of two or more stereoisomers, such as mixtures of enantiomers and / or diastereomers in any proportion.
[0095] As used herein, "isotopically labeled" refers to a molecule in which one or more atoms are replaced by atoms having a different atomic mass or mass number. Examples of isotopes that may be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, such as, but not limited to, 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 35 S. 18 F. 36 Cl, 123 I and 125 I. Certain isotopically labeled compounds of the present invention may be used in drug and / or substrate tissue distribution studies. Radioactive isotopes such as tritium, 3H and carbon-14 14 C is particularly useful for this purpose due to its ease of incorporation and convenient means of detection. For example, the compounds of the invention may be enriched with 1%, 2%, 5%, 10%, 25%, 50%, 75%, 90%, 95% or 99% of a given isotope. In addition, the use of heavier isotopes such as deuterium, i.e. 2 H-substituted compounds of the invention may offer certain therapeutic advantages.
[0096] The term "pharmaceutically acceptable salt" as used herein refers to a salt of a compound of the present invention formed with an acid or base suitable for pharmaceutical use. The aforementioned acids and bases are broadly defined as Lewis acids and bases. Suitable acids for forming salts include inorganic acids, organic acids, and acidic amino acids.
[0097] The "solvate" of the present invention refers to an association compound suitable for use as a drug formed by one or more solvent molecules and the compound of the present invention. Solvents that form solvates include water and organic solvents.
[0098] In the present invention, "optionally substituted with..." means that the group may be substituted with one or more (including two) designated substituents, or may be unsubstituted.
[0099] In the present invention, "ring" refers to any covalently closed structure, including, for example, a carbocyclic ring (e.g., an aryl or cycloalkyl group), a heterocyclic ring (e.g., a heteroaryl or heterocycloalkyl group), an aromatic group (e.g., an aryl or heteroaryl group), and a non-aromatic group (e.g., a cycloalkyl or heterocycloalkyl group). The "ring" of the present invention can be a monocyclic ring or a polycyclic ring (including a bicyclic ring), and can be a fused ring, a spirocyclic ring, or a bridged ring.
[0100] In the present invention, "member" represents the number of ring atoms constituting the ring skeleton.
[0101] The term "halogen" includes F, Cl, Br or I.
[0102] The term "alkyl" refers to a straight-chain or branched saturated aliphatic hydrocarbon group. "C1-C6 alkyl" refers to a straight-chain or branched saturated aliphatic hydrocarbon group having 1, 2, 3, 4, 5, or 6 carbon atoms, examples of which include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, and the like. As otherwise indicated, the alkyl group may be optionally substituted with one or more suitable substituents.
[0103] The term "alkoxy" refers to an "alkyl" group as defined above attached via an oxygen atom, i.e., an "alkoxy" group can be defined as -OR, wherein R is an alkyl group as defined above. Examples of "C1-C6 alkoxy" include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy, and the like. As otherwise indicated, the alkoxy group may be optionally substituted with one or more suitable substituents.
[0104] The term "alkenyl" refers to a straight or branched aliphatic hydrocarbon group containing at least one carbon-carbon double bond (i.e., C=C). The double bond can exist as an E or Z isomer. The double bond can be located at any possible position of the hydrocarbon chain. As otherwise indicated, the alkenyl group is optionally substituted with one or more suitable substituents.
[0105] The term "aliphatic carbocycle" refers to a non-aromatic carbocyclic ring system having 3 or more ring carbon atoms and no heteroatoms in the ring backbone. A "5- to 6-membered aliphatic carbocycle" refers to a non-aromatic carbocyclic ring having 5-6 ring carbon atoms. As otherwise indicated, the aliphatic carbocycle may be optionally substituted with one or more suitable substituents.
[0106] The term "cycloalkyl" refers to a saturated monocyclic or polycyclic hydrocarbon group. "3-10 membered cycloalkyl" refers to a saturated monocyclic or polycyclic hydrocarbon ring with 3-10 ring carbon atoms, examples of which include but are not limited to cyclopropane, cyclobutane, bicyclo[1.1.1]pentane, etc. The structural formula of cyclopropane is The structural formula of cyclobutane is The structural formula of bicyclo[1.1.1]pentane is If otherwise indicated, the cycloalkyl group is optionally substituted with one or more suitable substituents.
[0107] The term "heterocycloalkyl" refers to a saturated monocyclic or polycyclic group, wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon. The heteroatom is preferably N, O, or S. "3-10 membered heterocycloalkyl" refers to a saturated monocyclic or polycyclic group having 3-10 ring atoms, wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon. Examples of 3-10 membered heterocycloalkanes include, but are not limited to: If otherwise indicated, the heterocycloalkyl group is optionally substituted with one or more suitable substituents.
[0108] The term "cycloalkenyl" refers to a non-aromatic, monocyclic or polycyclic carbocyclic hydrocarbon radical containing at least one carbon-carbon double bond (i.e., C=C). "3-10 membered cycloalkenyl" refers to an unsaturated, non-aromatic, monocyclic or polycyclic carbocyclic hydrocarbon radical having 3 to 10 ring carbon atoms. As otherwise indicated, the cycloalkenyl radical is optionally substituted with one or more suitable substituents.
[0109] The term "heterocycloalkenyl" refers to a non-aromatic monocyclic or polycyclic group containing at least one double bond, wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon. Heteroatoms include, but are not limited to, N, O, S, P, Si, and the like, preferably N, O, and S. As otherwise indicated, the heterocycloalkenyl group may be optionally substituted with one or more suitable substituents.
[0110] The term "aryl" refers to an all-carbon monocyclic or polycyclic aromatic group having a conjugated π electron system, including monocyclic aromatic groups (e.g., 6-membered phenyl), fused-ring aromatic groups (having aromatic rings and aromatic rings sharing a ring edge, such as 10-membered naphthyl), and biaryl groups (connected by a single bond to form an aryl-aryl structure, such as 12-membered biphenyl). As otherwise indicated, the aryl group is optionally substituted with one or more suitable substituents.
[0111] The term "heteroaryl" refers to a monocyclic or polycyclic aromatic group with a conjugated π electron system, wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon. The heteroatom is preferably N, O, or S. The heteroaryl groups described in the present invention include monocyclic heteroaryl groups (such as 5-membered pyrazolyl, imidazolyl, 1,2,3-triazolyl, and 1,2,4-triazolyl), fused ring heteroaryl groups (having heteroaromatic rings and heteroaromatic rings sharing a ring edge, or aromatic rings and heteroaromatic rings sharing a ring edge), and bicyclic heteroaryl groups (forming a heteroaryl-heteroaryl structure or an aryl-heteroaryl structure connected by a single bond). Examples of 5- to 10-membered heteroaromatic hydrocarbons include, but are not limited to: If otherwise indicated, the heteroaryl group is optionally substituted with one or more suitable substituents.
[0112] The pharmaceutically acceptable excipients described in the present invention are a general term for all additional materials in a drug other than the main drug. Excipients should have the following properties: (1) no toxic effects on the human body and almost no side effects; (2) stable chemical properties and not easily affected by temperature, pH, storage time, etc.; (3) no incompatibility with the main drug and no impact on the efficacy and quality inspection of the main drug; (4) no interaction with the packaging material. Excipients in the present invention include but are not limited to fillers (diluents), lubricants (glidants or anti-adhesives), dispersants, wetting agents, adhesives, regulators, solubilizers, antioxidants, antibacterial agents, emulsifiers, disintegrants, etc. There is no particular limitation on the mode of administration of the compound or pharmaceutical composition of the present invention. Representative modes of administration include (but are not limited to): oral, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.
[0113] The present invention provides a series of compounds with significant inhibitory effects on the SOS1 protein, offering new treatment options for diseases targeting SOS1, such as cancer and pathogenic rashes. Compared to existing SOS1 inhibitors, the compounds of the present invention exhibit significant improvements in activity and drugability, particularly improved metabolic stability in liver microsomes, weaker inhibition of liver drug-metabolizing enzymes, higher oral bioavailability, and excellent drugability. These compounds can be used to prepare drugs for treating related diseases, offering broad application prospects. DETAILED DESCRIPTION
[0114] The following is a clear and complete description of the technical solution of the present invention. Obviously, the embodiments described are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making any creative efforts are within the scope of protection of the present invention.
[0115] The structures of the compounds of the present invention were determined by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts (δ) are given in parts per million (ppm). NMR measurements were performed using an AVANCE NEO 400 MHz Bruker instrument, using deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD) as the solvents, with tetramethylsilane (TMS) as the internal standard. MS measurements were performed using an ISQ-EC Thermo Fisher LC-MS instrument. Prep-HPLC was performed on a GX-281 Gilson chromatograph, and the separation methods were as follows: (Method 1) Sun Fire Prep C18 OBDTM 5 μm, 30×150 mm Column, 0.04% aqueous HCl solution / acetonitrile; (Method 2) Sun Fire Prep C18 OBDTM 5 μm, 30×150 mm Column, 0.06% aqueous formic acid solution / acetonitrile; (Method 3) Xbridge Prep C18 OBDTM 5 μm, 30×150 mm Column, 10 mM aqueous NH4HCO3 solution / acetonitrile; (Method 4) SunFire Prep C18 OBDTM 5 μm, 30×150 mm Column, 0.02% aqueous CF3COOH trifluoroacetic acid solution / acetonitrile.
[0116] The starting materials in the examples of the present invention are known and can be purchased on the market, or can be synthesized according to methods known in the art.
[0117] Unless otherwise specified, the solvents used in the present invention are commercially available.
[0118] Unless otherwise specified in the examples, the reaction temperature is room temperature, 20°C to 30°C.
[0119] The chemical abbreviations used in the present invention have the following meanings:
[0120] DMF: N,N-dimethylformamide
[0121] DMSO: dimethyl sulfoxide
[0122] DIPEA: N,N-diisopropylethylamine
[0123] DMF-DMA: N,N-dimethylformamide dimethyl acetal
[0124] Prep-HPLC: Preparative High Performance Liquid Chromatography
[0125] Example 1
[0126] Preparation of (R)-6-cyclopropyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(1H-1,2,4-triazol-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one
[0127] Step a): Preparation of dimethyl 2-formyl-3-oxoglutarate
[0128] Dimethyl 3-oxoglutarate (5.0 g, 28.711 mmol) and 1-methyltetrahydrofuran (100 mL) were added to a reaction flask. DMF-DMA (4.1 g, 34.454 mmol) was added dropwise under an ice-water bath. After addition, the mixture was allowed to warm to room temperature and react for 2 h. Hydrochloric acid (100 mL, 4 N) was added to the reaction solution, and the reaction was continued at room temperature for 1 h. After completion of the reaction, the reaction solution was extracted with ethyl acetate (100 mL of ethyl acetate). The combined organic phases were washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain dimethyl 2-formyl-3-oxoglutarate in a yield of 99.9%; ESI-MS (m / z): 203.2 [M+H] + .
[0129] Step b): Preparation of methyl 1-cyclopropyl-4-hydroxy-6-oxo-1,6-dihydropyridine-3-carboxylate
[0130] Dimethyl 2-formyl-3-oxoglutarate (5.6 g, 27.716 mmol), cyclopropylamine (1.9 g, 33.259 mmol), sodium methoxide (3.5 mg, 60.975 mmol), and methanol (50 mL) were added to a reaction flask and heated to 80°C for 2 h. After completion of the reaction, the mixture was cooled to room temperature and quenched with saturated aqueous ammonium chloride (50 mL). The reaction mixture was adjusted to pH 2-3 with 4N hydrochloric acid and extracted with dichloromethane (20 mL x 3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain methyl 1-cyclopropyl-4-hydroxy-6-oxo-1,6-dihydropyridine-3-carboxylate, which was used directly in the next step without purification in an 82.2% yield. ESI-MS (m / z): 210.0 [M+H] + .
[0131] Step c): Preparation of methyl 1-cyclopropyl-6-oxo-4-(((trifluoromethyl)sulfonyl)oxy)-1,6-dihydropyridine-3-carboxylate
[0132] Dissolve methyl 1-cyclopropyl-4-hydroxy-6-oxo-1,6-dihydropyridine-3-carboxylate (4.8 g, 22.967 mmol) in dichloromethane (50 mL). Add pyridine (3.6 g, 45.934 mmol) under ice-cooling. Slowly add trifluoromethanesulfonic anhydride (9.7 g, 34.450 mmol) dropwise. After addition, warm to room temperature and react for 20 min. Quench the reaction with saturated aqueous ammonium chloride (50 mL) and extract with dichloromethane (20 mL, 1% HCl). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1) to obtain methyl 1-cyclopropyl-6-oxo-4-(((trifluoromethyl)sulfonyl)oxy)-1,6-dihydropyridine-3-carboxylate in a yield of 60.5%; ESI-MS (m / z): 342.0 [M+H] + .
[0133] Step d): Preparation of methyl 4-cyano-1-cyclopropyl-6-oxo-1,6-dihydropyridine-3-carboxylate
[0134] At room temperature, 1-cyclopropyl-6-oxo-4-(((trifluoromethyl)sulfonyl)oxy)-1,6-dihydropyridine-3-carboxylic acid methyl ester (4.1 g, 12.113 mmol), zinc cyanide (2.2 g, 24.226 mmol), tetrakistriphenylphosphine palladium (280 mg, 0.242 mmol) and DMF (20 mL) were added to the reaction flask, nitrogen was replaced three times, the temperature was raised to 80 ° C, the reaction was carried out for 1 h, the reaction was cooled and filtered, and the filtrate was poured into water. The product was added to 4-nitro-1-cyclopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid methyl ester (100%), and the mixture was added to 4-nitro-1-cyclopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid methyl ester (100%). The product was added to 4-nitro-1-cyclopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid methyl ester (100%). The yield was 78.2%. ESI-MS (m / z): 219.0 [M+H] + .
[0135] Step e): dimethyl 1-cyclopropyl-6-oxo-1,6-dihydropyridine-3,4-dicarboxylate
[0136] Methyl 4-cyano-1-cyclopropyl-6-oxo-1,6-dihydropyridine-3-carboxylate (2.1 g, 9.633 mmol) and 6N hydrochloric acid (10 mL) were added to a reaction flask at room temperature. The temperature was raised to reflux for 5 hours, and methanol (40 mL) was added. The reaction was continued at reflux overnight. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was extracted with water (30 mL) and ethyl acetate (50 mL of methanol). The combined organic phases were washed with saturated sodium bicarbonate (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain dimethyl 1-cyclopropyl-6-oxo-1,6-dihydropyridine-3,4-dicarboxylate, which was used directly in the next reaction without purification in a yield of 75.1%. ESI-MS (m / z): 252.0 [M+H] + .
[0137] Step f): 6-cyclopropyl-2,3-dihydropyrido[3,4-d]pyridazine-1,4,7(6H)-trione
[0138] Dimethyl 1-cyclopropyl-6-oxo-1,6-dihydropyridine-3,4-dicarboxylate (1.6 g, 6.375 mmol) and hydrazine hydrate (10 mL, 80%) were added to a reaction flask at room temperature and heated to 100°C for overnight reaction. After the reaction was completed, the mixture was cooled to room temperature and acetonitrile (100 mL) was added. A large amount of solid precipitated and was filtered. The filter cake was rinsed with acetonitrile (10 mL) and then dried under reduced pressure to obtain 6-cyclopropyl-2,3-dihydropyrido[3,4-d]pyridazine-1,4,7(6H)-trione in a 68.3% yield. ESI-MS (m / z): 220.0 [M+H] + .
[0139] Step g): Preparation of 6-cyclopropyl-1,4-di(1H-1,2,4-triazol-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one
[0140] 6-Cyclopropyl-2,3-dihydropyrido[3,4-d]pyridazine-1,4,7(6H)-trione (3.0 g, 13.686 mmol), triethylamine (33.2 g, 328.096 mmol) and acetonitrile (90 mL) were added to a reaction flask, and a solution of phosphorus oxychloride (12.6 g, 82.176 mmol) in acetonitrile (20 mL) was added dropwise. After the addition was completed, the mixture was stirred at room temperature for 5 min, and 1,2,4-triazole (22.7 g, The reaction mixture was stirred at room temperature for 15 min, and then concentrated under reduced pressure, poured into ice water (80 mL), stirred at room temperature for 10 min, filtered, and the filter cake was rinsed with water (20 mL × 3) and dried in vacuo to obtain 6-cyclopropyl-1,4-bis(1H-1,2,4-triazol-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one with a yield of 71.2%; ESI-MS (m / z): 322.2 [M+H] + .
[0141] Step h): Preparation of (R)-6-cyclopropyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(1H-1,2,4-triazol-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one
[0142] 6-Cyclopropyl-1,4-di(1H-1,2,4-triazol-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one (160 mg, 0.498 mmol), (R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethane-1-amine hydrochloride (110 mg, 0.488 mmol) and 1,4-dioxane (8 mL) were added to the reaction flask, and the temperature was raised to reflux with stirring for 2 h. After the reaction, the product was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 96 / 4). The crude product was further purified by Prep-HPLC (Separation Method 3) to obtain (R)-6-cyclopropyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(1H-1,2,4-triazol-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 6.1%. 1H NMR(400MHz, DMSO-d6)δ9.29(s,1H),9.06(s,1H),8.68(s,1H),8.34(s,1H),7.69(t,J=7.2Hz,1H),7.53(t,J=6.8Hz,1H),7.39-7.12(m, 2H),6.67(s,1H),5.77-5.69(m,1H),3.71-3.63(m,1H),1.64(d,J=7.2Hz,3H),1.22-1.14(m,4H); ESI-MS(m / z): 442.0[M+H] + .
[0143] Example 2
[0144] Preparation of (R)-1-chloro-6-cyclopropyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)pyrido[3,4-d]pyridazin-7(6H)-one
[0145] Step a): Preparation of 1,4-dichloro-6-cyclopropylpyrido[3,4-d]pyridazin-7(6H)-one
[0146] 6-Cyclopropyl-2,3-dihydropyrido[3,4-d]pyridazine-1,4,7(6H)-trione (8.8 g, 68.493 mmol) and acetonitrile (500 mL) were added to a reaction flask. DIPEA (26.5 g, 205.479 mmol) and phosphorus oxychloride (31.5 g, 205.479 mmol) were added under stirring at room temperature. The temperature was raised to 100 ° C under nitrogen protection and the reaction was carried out for 3 h. After the reaction, the mixture was cooled to room temperature and slowly poured into a mixture of ice and sodium bicarbonate to quench the mixture. The mixture was extracted with dichloromethane (100 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 49 / 1) to obtain 1,4-dichloro-6-cyclopropylpyrido[3,4-d]pyridazin-7(6H)-one in a yield of 5.6%; ESI-MS (m / z): 256.0 [M+H] + .
[0147] Step b): Preparation of (R)-1-chloro-6-cyclopropyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)pyrido[3,4-d]pyridazin-7(6H)-one
[0148] 1,4-Dichloro-6-cyclopropylpyrido[3,4-d]pyridazin-7(6H)-one (500 mg, 1.953 mmol), (R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethane-1-amine hydrochloride (439 mg, 1.953 mmol), and 1,4-dioxane (10 mL) were added to a microwave reaction vial and heated to 120°C in a microwave oven for 2 hours. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by Prep-HPLC (Separation Method 3) to obtain (R)-1-chloro-6-cyclopropyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 26.6%. 1 H NMR (400MHz, DMSO-d6) δ9.14(s,1H),8.14(d,J=6.8Hz,1H),7.63(t,J=7.6Hz,1H),7.50(t,J=7.2Hz,1H),7.28(t,J=7.6Hz,1H),7.24(t ,J=56.0Hz,1H),6.51(s,1H),5.66-5.59(m,1H),3.66-3.60(m,1H),1.58(d,J=7.2Hz,3H),1.20-1.09(m,4H); ESI-MS(m / z): 409.0[M+H] + .
[0149] With reference to the preparation method of Example 2, the compounds in the following examples were prepared using corresponding raw materials.
[0150] Example 4
[0151] Preparation of (R)-6-cyclopropyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(pyrrolidin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one
[0152] (R)-1-chloro-6-cyclopropyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)pyrido[3,4-d]pyridazin-7(6H)-one (150 mg, 0.368 mmol), tetrahydropyrrole (52 mg, 0.735 mmol), and 1,4-dioxane (2 mL) were added to a microwave reaction vial and heated to 100°C for 1 hour. After completion of the reaction, the product was concentrated under reduced pressure, and the residue was purified by Prep-HPLC (Separation Method 3) to obtain (R)-6-cyclopropyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(pyrrolidin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 27.6%. 1 H NMR (400MHz, DMSO-d6) δ8.87(s,1H),7.60(t,J=7.6Hz,1H),7.47(t,J=7.2Hz,1H),7.27-7.25(m,2H),7.24(t,J=56.0Hz,1H),6.65(s,1H),5. 55-5.48(m,1H),3.66-3.59(m,1H),3.43-3.35(m,4H),1.87-1.77(m,4 H),1.52(d,J=7.2Hz,3H),1.19-1.09(m,4H); ESI-MS(m / z):444.0[M+H] + .
[0153] With reference to the preparation method of Example 4, the compounds in the following examples were prepared using corresponding raw materials.
[0154] Example 30
[0155] Preparation of (R)-6-cyclopropyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(1H-pyrazol-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one
[0156] (R)-1-chloro-6-cyclopropyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)pyrido[3,4-d]pyridazin-7(6H)-one (40 mg, 0.098 mmol), pyrazole (20 mg, 0.293 mmol), and 1,4-dioxane (2 mL) were added to a microwave reaction vial and heated to 100°C for 1 hour. After the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by Prep-HPLC (Separation Method 3) to obtain (R)-6-cyclopropyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(1H-pyrazol-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 23.6%. 1 HNMR(400MHz,DMSO-d6)δ9.17(s,1H),8.25(s,1H),8.20(d,J=6.8Hz,1H),7.83( s,1H),7.67(t,J=7.6Hz,1H),7.51(t,J=7.2Hz,1H),7.29(t,J=7.6Hz,1H),7.25 (t,J=56.0Hz,1H),6.97(s,1H),6.52(t,J=2.0Hz,1H),5.77-5.68(m,1H),3.69- 3.62(m,1H),1.60(d,J=7.2Hz,3H),1.22-1.11(m,4H); ESI-MS(m / z): 441.0[M+H] + .
[0157] With reference to the preparation method of Example 30, the compounds in the following examples were prepared using corresponding raw materials.
[0158] Example 35
[0159] Preparation of 3-((1R)-1-((1-(3-azabicyclo[3.1.0]hexan-3-yl)-6-cyclopropyl-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)-2-methylbenzonitrile
[0160] Step a): Preparation of (R)-3-(1-((1-chloro-6-cyclopropyl-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)-2-methylbenzonitrile.
[0161] 1,4-Dichloro-6-cyclopropylpyrido[3,4-d]pyridazin-7(6H)-one (230 mg, 0.898 mmol), (R)-3-(1-aminoethyl)-2-methylbenzonitrile hydrochloride (194 mg, 0.988 mmol), N,N-diisopropylethylamine (290 mg, 2.245 mmol) and DMSO (10 mL) were added to the reaction flask, and the temperature was raised to 120 °C under nitrogen protection for 1 h. After the reaction, the mixture was cooled to room temperature, ethyl acetate (100 mL) was added, and the mixture was washed with saturated brine (30 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 3) to obtain (R)-3-(1-((1-chloro-6-cyclopropyl-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)-2-methylbenzonitrile in a yield of 76.1%; ESI-MS (m / z): 380.1 [M+H] + .
[0162] Step b): Preparation of 3-((1R)-1-((1-(3-azabicyclo[3.1.0]hexan-3-yl)-6-cyclopropyl-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)-2-methylbenzonitrile.
[0163] (R)-3-(1-((1-chloro-6-cyclopropyl-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)-2-methylbenzonitrile (50 mg, 0.132 mmol), 3-azabicyclo[3.1.0]hexane (47 mg, 0.396 mmol) and 1,4-dioxane (2 mL) were added to a microwave reaction bottle and heated to 120°C in a microwave apparatus for 1 h. After the reaction, the product was concentrated under reduced pressure and the residue was purified by Prep-HPLC (Separation Method 3) to obtain 3-((1R)-1-((1-(3-azabicyclo[3.1.0]hexan-3-yl)-6-cyclopropyl-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)-2-methylbenzonitrile in a yield of 27.6%. 1H NMR (400MHz, DMSO-d6) δ8.89(s,1H),7.72(d,J=7.6Hz,1H),7.62(d,J=7.6Hz,1H),7.42(d ,J=6.4Hz,1H),7.34(t,J=7.6Hz,1H),6.48(s,1H),5.43-5.38(m,1H),3.64-3.54(m,2H),3 .49(d,J=10.0Hz,1H),3.30-3.22(m,2H),2.60(s,3H),1.52-1.50(m,2H),1.46(d,J=7.2H z,3H),1.17-1.13(m,2H),1.12-1.07(m,2H),0.55-0.48(m,2H); ESI-MS(m / z): 427.0[M+H] + .
[0164] With reference to the preparation method of Example 35, the compounds in the following examples were prepared using corresponding starting materials.
[0165] Example 49
[0166] Preparation of (R)-6-cyclopropyl-4-((1-(2-methyl-3-(trifluoromethyl)phenyl)ethyl)amino)-1-(pyrrolidin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one
[0167] Step a): Preparation of (R)-1-chloro-6-cyclopropyl-4-((1-(2-methyl-3-(trifluoromethyl)phenyl)ethyl)amino)pyrido[3,4-d]pyridazin-7(6H)-one
[0168] 1,4-Dichloro-6-cyclopropylpyrido[3,4-d]pyridazin-7(6H)-one (320 mg, 1.250 mmol), (R)-1-(2-methyl-3-(trifluoromethyl)phenyl)ethane-1-amine hydrochloride (329 mg, 1.375 mmol), N,N-diisopropylethylamine (485 mg, 3.750 mmol) and dimethyl sulfoxide (8 mL) were added to a reaction flask and the temperature was raised to 120°C for 1 h. After completion of the reaction, the mixture was cooled to room temperature and quenched with saturated aqueous ammonium chloride solution (50 mL). The mixture was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1:4) to obtain (R)-1-chloro-6-cyclopropyl-4-((1-(2-methyl-3-(trifluoromethyl)phenyl)ethyl)amino)pyrido[3,4-d]pyridazin-7(6H)-one; yield: 59.0%; ESI-MS (m / z): 423.1 [M+H] + .
[0169] Step b): Preparation of (R)-6-cyclopropyl-4-((1-(2-methyl-3-(trifluoromethyl)phenyl)ethyl)amino)-1-(pyrrolidin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one
[0170] (R)-1-chloro-6-cyclopropyl-4-((1-(2-methyl-3-(trifluoromethyl)phenyl)ethyl)amino)pyrido[3,4-d]pyridazin-7(6H)-one (50 mg, 0.118 mmol), tetrahydropyrrole (42 mg, 0.591 mmol), and 1,4-dioxane (2 mL) were added to a microwave tube and heated to 120°C for 1 hour. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by Prep-HPLC (Separation Method 3) to obtain (R)-6-cyclopropyl-4-((1-(2-methyl-3-(trifluoromethyl)phenyl)ethyl)amino)-1-(pyrrolidin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 40.7%. 1H NMR(400MHz,DMSO-d6)δ8.86(s,1H),7.73(d,J=7.6Hz,1H),7.53(d,J=7.6H z,1H),7.34(t,J=7.6Hz,1H),7.28(d,J=6.8Hz,1H),6.63(s,1H),5.50(p,J =6.8Hz,1H),3.64-3.57(m,1H),3.41-3.34(m,4H),2.51(s,3H),1.85-1.77 (m,4H),1.47(d,J=6.9Hz,3H),1.17-1.09(m,4H); ESI-MS(m / z): 458.2[M+H] + .
[0171] With reference to the preparation method of Example 49, the compounds in the following examples were prepared using corresponding starting materials.
[0172] Example 74
[0173] Preparation of (R)-1-amino-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one formate
[0174] Step a): Preparation of (R)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(4-methoxybenzyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one
[0175] (R)-1-chloro-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one (300 mg, 0.710 mmol), 4-methoxybenzylamine (320 mg, 3.500 mmol), and 1,4-dioxane (3 mL) were added to a reaction flask and heated to 115°C for 30 min. After completion of the reaction, the mixture was cooled to room temperature, and the residue was concentrated under reduced pressure to obtain (R)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(4-methoxybenzyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 93.1%; ESI-MS (m / z): 524.0 [M+H] + .
[0176] Step b): Preparation of (R)-1-amino-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one formate
[0177] (R)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(4-methoxybenzyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one (260 mg, 0.497 mmol) and trifluoroacetic acid (5 mL) were added to a reaction flask, and the temperature was raised to 85°C and stirred for 20 minutes. After completion of the reaction, the mixture was concentrated under reduced pressure, and the residue was purified by Prep-HPLC (Separation Method 2) to obtain (R)-1-amino-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one formate in a yield of 6.1%. 1 H NMR (400MHz, DMSO-d6) δ9.05(s,1H),8.18(s,1H),7.60(t,J=7.6Hz,1H),7.46(t,J=7.2Hz,1H),7.36-7.09(m,2H),7.06-6.9 8(m,1H),6.82(s,1H),5.97-5.81(m,2H),5.49-5.40(m,1H),1.56-1.48(m,6H),1.21-1.03(m,4H); ESI-MS(m / z): 404.0[M+H] + .
[0178] Referring to the preparation method of Example 74, the compounds in the following examples were prepared with corresponding starting materials.
[0179] Example 76
[0180] Preparation of (R)-6-cyclopropyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(dimethylamino)pyrido[3,4-d]pyridazin-7(6H)-one
[0181] (R)-6-cyclopropyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(1H-1,2,4-triazol-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one (100 mg, 0.227 mmol), dimethylamine hydrochloride (190 mg, 2.330 mmol), and 1,4-dioxane (5 mL) were added to a microwave reaction vial and heated to 110°C for 4 hours. After completion of the reaction, the product was concentrated under reduced pressure, and the residue was purified by Prep-HPLC (Separation Method 3) to obtain (R)-6-cyclopropyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(dimethylamino)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 6.2%. 1 HNMR (400MHz, DMSO-d6) δ8.96 (s, 1H), 7.61 (t, J = 7.2Hz, 1H), 7.54-7.44 (m, 2H), 7.38-7.10 (m, 2H), 6.49 (s, 1H), 5.6 1-5.49(m,1H),3.67-3.56(m,1H),2.70(s,6H),1.53(d,J=7.2Hz,3H),1.18-1.09(m,4H)); ESI-MS(m / z): 418.0[M+H] + .
[0182] Referring to the preparation method of Example 76, the compounds in the following examples were prepared with corresponding starting materials.
[0183] Example 78
[0184] Preparation of (R)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)-1-(piperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one
[0185] Step a): Preparation of tert-butyl (R)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-1-yl)piperazine-1-carboxylate
[0186] The preparation method was prepared by referring to Example 4 to obtain tert-butyl (R)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-1-yl)piperazine-1-carboxylate in a yield of 97.1%; ESI-MS (m / z): 573.3 [M+H]+ .
[0187] Step b): Preparation of (R)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)-1-(piperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one
[0188] tert-Butyl (R)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-1-yl)piperazine-1-carboxylate (230 mg, 0.402 mmol), 1,4-dioxane (2 mL), and a 1,4-dioxane solution of hydrogen chloride (8 mL, 4 M) were added to a reaction flask and stirred at room temperature for 1 hour. After completion of the reaction, the product was concentrated under reduced pressure, and the residue was purified by Prep-HPLC (Separation Method 3) to obtain (R)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)-1-(piperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 22.0%. 1 H NMR (400MHz, DMSO-d6) δ9.22(s,1H),7.62(t,J=7.2Hz,1H),7.55(d,J=6.8Hz,1H),7.48(t,J=6.8Hz,1H),7.38-7.11(m,2H),6.41 (s,1H),5.61-5.51(m,1H),2.95-2.86(m,4H),2.86-2.80(m,4H),1.58-1.49(m,6H),1.20-1.04(m,4H); ESI-MS(m / z): 473.0[M+H] + .
[0189] Example 79
[0190] Preparation of (R)-1-(4-acetylpiperazin-1-yl)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one
[0191] (R)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)-1-(piperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one (142 mg, 0.279 mmol), triethylamine (120 mg, 1.186 mmol) and dichloromethane (10 mL) were added to a reaction flask, and a solution of acetyl chloride (22 mg, 0.280 mmol) in dichloromethane (1 mL) was added dropwise, and the reaction was carried out at room temperature for 30 min. The reaction was quenched with saturated aqueous sodium bicarbonate (30 mL), extracted with dichloromethane (30 mL × 2), and the combined organic phases were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by Prep-HPLC (Separation Method 3) to obtain (R)-1-(4-acetylpiperazin-1-yl)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 14.8%. 1 H NMR(400MHz,DMSO-d6)δ9.28(s,1H),7.71-7.43(m,3H),7.38-7.11(m,2H),6.51(s,1H),5.61-5.47(m,1H),3.6 3-3.55(m,4H),3.08-2.90(m,4H),2.02(s,3H),1.61-1.50(m,6H),1.21-1.06(m,4H); ESI-MS(m / z): 515.0[M+H] + .
[0192] Example 80
[0193] Preparation of (R)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)-1-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one formate
[0194] Step af): Preparation of 6-(1-methylcyclopropyl)-2,3-dihydropyrido[3,4-d]pyridazine-1,4,7(6H)-trione
[0195] Preparation method: Refer to steps af of Example 1 to obtain 6-(1-methylcyclopropyl)-2,3-dihydropyrido[3,4-d]pyridazine-1,4,7(6H)-trione; ESI-MS (m / z): 234.1 [M+H] + .
[0196] Step g): Preparation of 1,4-dichloro-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one
[0197] 6-(1-Methylcyclopropyl)-2,3-dihydropyrido[3,4-d]pyridazine-1,4,7(6H)-trione (300 mg, 1.286 mmol) and acetonitrile (30 mL) were added to the reaction flask. DIPEA (499 mg, 3.858 mmol) and phosphorus oxychloride (592 mg, 3.858 mmol) were added under stirring at room temperature. The temperature was raised to 100 °C under nitrogen protection and the reaction was carried out for 3 h. After the reaction, the mixture was cooled to room temperature and slowly poured into a mixture of ice and sodium bicarbonate to quench the reaction mixture. The mixture was extracted with dichloromethane (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 50 / 1) to obtain 1,4-dichloro-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 22.5%; ESI-MS (m / z): 270.0 [M+H] + .
[0198] Step h): Preparation of (R)-1-chloro-4-((1-(3-(difluoromethyl)-2-difluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one
[0199] 1,4-Dichloro-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one (75 mg, 0.278 mmol), (R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethane-1-amine hydrochloride (63 mg, 0.278 mmol) and 1,4-dioxane (2 mL) were added to a microwave reaction bottle and heated to 120°C in a microwave apparatus for 2 h. After the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 30 / 1) to obtain (R)-1-chloro-4-((1-(3-(difluoromethyl)-2-difluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 73.9%; ESI-MS (m / z): 423.2 [M+H] + .
[0200] Step i): Preparation of (R)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)-1-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one formate
[0201] (R)-1-chloro-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one (50 mg, 0.118 mmol), 4-methylpiperazine (36 mg, 0.359 mmol), and 1,4-dioxane (1 mL) were added to a reaction flask and heated to 110°C for 30 minutes. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by Prep-HPLC (Separation Method 2) to obtain (R)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-6-(1-methylcyclopropyl)-1-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one formate in a yield of 36.2%. 1 H NMR (400MHz, DMSO-d6) δ9.22(s,1H),8.16(s,1H),7.62(t,J=7.2Hz,1H),7.57(d,J=6.8Hz,1H),7.48(t,J=6.8Hz,1H),7.38-7.11(m,2H),6.39 (s,1H),5.62-5.51(m,1H),3.05-2.95(m,4H),2.50-2.41(m,4H),2.23( s,3H),1.59-1.49(m,6H),1.20-1.03(m,4H); ESI-MS(m / z): 487.0[M+H] + .
[0202] Example 81
[0203] Preparation of (R)-4-((1-(2-methyl-3-(trifluoromethyl)phenyl)ethyl)amino)-6-(1-methylcyclopropyl)-1-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one
[0204] Preparation method: With reference to Example 80, the crude product was purified by Prep-HPLC (Separation Method 3) to give (R)-4-((1-(2-methyl-3-(trifluoromethyl)phenyl)ethyl)amino)-6-(1-methylcyclopropyl)-1-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 37.3%; 1H NMR(400MHz,DMSO-d6)δ9.22(s,1H),7.74(d,J=7.8Hz,1H),7.58(d,J=6.8Hz ,1H),7.54(d,J=7.8Hz,1H),7.35(t,J=7.8Hz,1H),6.39(s,1H),5.55(p,J=6. 8Hz,1H),3.29-3.26(m,4H),3.12-2.87(m,4H),2.51(s,3H)2.26(s,3H),1.5 4(s,3H),1.49(d,J=6.9Hz,3H),1.20-1.04(m,4H); ESI-MS(m / z):501.2[M+H] + .
[0205] Example 82
[0206] Preparation of (R)-2-methyl-3-(1-((6-(1-methylcyclopropyl)-1-(4-methylpiperazin-1-yl)-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)benzonitrile
[0207] Preparation method: Refer to Example 80, and the resulting crude product is purified by Prep-HPLC (Separation Method 3) to obtain (R)-2-methyl-3-(1-((6-(1-methylcyclopropyl)-1-(4-methylpiperazin-1-yl)-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)benzonitrile in a yield of 41.0%; 1 H NMR (400MHz, DMSO-d6) δ9.20 (s, 1H), 7.74 (d, J = 8.0Hz, 1H), 7.63 (d, J = 7.2Hz, 1H), 7.58 (d, J = 6.4Hz, 1H), 7.36 (t, J = 7.6Hz, 1H), 6.39 (s, 1H), 5.49-5. 42(m,1H),3.00-2.97(m,4H),2.62(s,3H),2.46(s,4H),2.22(s,3H),1.54( s,3H),1.49(d,J=7.2Hz,3H),1.19-1.04(m,4H); ESI-MS(m / z):458.3[M+H] + .
[0208] Example 83
[0209] Preparation of (R)-2-methyl-3-(1-((1-(methylamino)-6-(1-methylcyclopropyl)-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)benzonitrile
[0210] Preparation method: Refer to Example 80. The crude product was purified by Prep-HPLC (Separation Method 3) to obtain (R)-2-methyl-3-(1-((1-(methylamino)-6-(1-methylcyclopropyl)-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)benzonitrile in a yield of 37.2%; 1 H NMR (400MHz, DMSO-d6) δ9.01(s,1H),7.73(d,J=7.6Hz,1H),7.61(d,J=7.2Hz,1H),7.34(t,J=7.6Hz,1H),6.98(d,J=6.4Hz,1H),6.76(s,1H),6.41-6 .38(m,1H),5.38-5.31(m,1H),2.75(d,J=4.4Hz,3H),2.61(s,3H),1.53(s ,3H),1.46(d,J=6.8Hz,3H),1.17-1.03(m,4H); ESI-MS(m / z):389.2[M+H] + .
[0211] Example 84
[0212] Preparation of (R)-3-(1-((1-(dimethylamino)-6-(1-methylcyclopropyl)-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)-2-methylbenzonitrile
[0213] Preparation method: Refer to Example 80. The crude product was purified by Prep-HPLC (Separation Method 3) to obtain (R)-3-(1-((1-(dimethylamino)-6-(1-methylcyclopropyl)-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)-2-methylbenzonitrile in a yield of 39.7%; 1 H NMR (400MHz, DMSO-d6) δ9.17(s,1H),7.75(d,J=7.6Hz,1H),7.63(d,J=7.2Hz,1H),7.50(d,J=6.4Hz,1H),7.36(t,J=8.0Hz,1H),6.46( s,1H),5.48-5.41(m,1H),2.70(s,6H),2.62(s,3H),1.55(s,3H),1.49(d,J=6.8Hz,3H),1.18-1.06(m,4H); ESI-MS(m / z): 403.2[M+H] + .
[0214] Example 85
[0215] Preparation of 2-methyl-3-((R)-1-((6-(1-methylcyclopropyl)-1-((R)-2-methylpyrrolidin-1-yl)-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)benzonitrile
[0216] Preparation method: With reference to Example 80, the crude product was purified by Prep-HPLC (Separation Method 3) to give 2-methyl-3-((R)-1-((6-(1-methylcyclopropyl)-1-((R)-2-methylpyrrolidin-1-yl)-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)benzonitrile in a yield of 29.0%; 1 H NMR(400MHz,DMSO-d6)δ9.12(s,1H),7.77(d,J=8.0Hz,1H),7.63(d,J=7.2Hz,1H),7.38 -7.33(m,2H),6.52(s,1H),5.46-5.39(m,1H),4.17-4.09(m,1H),3.69-3.63(m,1H),3. 09-3.04(m,1H),2.61(s,3H),2.12-2.05(m,1H),1.90-1.83(m,1H),1.72-1.63(m,1H), 1.54-1.47(m,7H),1.20-1.06(m,4H),0.95(d,J=4.8Hz,3H); ESI-MS(m / z): 443.2[M+H] + .
[0217] Example 86
[0218] Preparation of (R)-6-cyclopropyl-4-((1-(2-methyl-3-(trifluoromethyl)phenyl)ethyl)amino)-1-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one
[0219] Preparation method: Refer to Example 80. The crude product was purified by Prep-HPLC (Separation Method 3) to obtain (R)-6-cyclopropyl-4-((1-(2-methyl-3-(trifluoromethyl)phenyl)ethyl)amino)-1-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 17.5%; 1H NMR(400MHz, DMSO-d6)δ8.98(s,1H),7.73(d,J=7.6Hz,1H),7.60-7.52(m,2H),7.35(t,J=8.0Hz,1H),6.41(s,1H),5.61-5.52(m,1H), 3.65-3.58(m,1H),3.02-2.94(m,4H),2.49-2.43(m,7H),2.22(s,3H),1.52-1.46(m,3H),1.18-1.08(m,4H); ESI-MS(m / z): 487.0[M+H] + .
[0220] Example 87
[0221] Preparation of (R)-3-(1-((6-cyclopropyl-1-(4-methylpiperazin-1-yl)-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)-2-methylbenzonitrile
[0222] Preparation method: Refer to Example 80, and the resulting crude product is purified by Prep-HPLC (Separation Method 3) to obtain (R)-3-(1-((6-cyclopropyl-1-(4-methylpiperazin-1-yl)-7-oxo-6,7-dihydropyrido[3,4-d]pyridazin-4-yl)amino)ethyl)-2-methylbenzonitrile in a yield of 44.7%; 1 H NMR (400MHz, DMSO-d6) δ8.97(s,1H),7.73(d,J=8.0Hz,1H),7.63(d,J=7.6Hz,1H),7.60(s,J=6.8Hz,1H),7.35(t,J=8.0Hz,1H),6.41(s,1H),5.50-5. 43(m,1H),3.64-3.59(m,1H),2.99(s,4H),2.62(s,4H),2.47(s,3H),2.23( s,3H),1.48(d,J=7.2Hz,3H),1.17-1.09(m,4H); ESI-MS(m / z):444.2[M+H] + .
[0223] Example 88
[0224] Preparation of (R)-6-cyclobutyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one
[0225] Step a): Preparation of (E)-3-(cyclobutylamino)acrylonitrile
[0226] Cyclobutylamine (2.3 g, 32.394 mmol) and (E)-3-ethoxyacrylonitrile (3.5 g, 35.634 mmol) were added to a sealed tube and heated with stirring at 80°C for 20 h. After the reaction was completed, the mixture was cooled to room temperature to obtain a brown liquid (E)-3-(cyclobutylamino)acrylonitrile (3.8 g, crude product), which was used directly in the next step without further treatment; ESI-MS (m / z): 123.0 [M+H] + Step b): Preparation of methyl 5-cyano-1-cyclobutyl-2-oxo-1,2-dihydropyridine-4-carboxylate
[0227] (E)-3-(Cyclobutylamino)acrylonitrile (3.8 g, crude product) was dissolved in dichloromethane (50 mL), and DBU (4.9 g, 32.394 mmol) was added. After the addition was completed, dimethyl but-2-ynedioate (6.9 g, 48.591 mmol) was slowly added dropwise at 0°C. The reaction was stirred and continued at 0°C for 0.5 h. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 2) to obtain methyl 5-cyano-1-cyclobutyl-2-oxo-1,2-dihydropyridine-4-carboxylate in a yield of 31.9%; ESI-MS (m / z): 233.0 [M+H] + .
[0228] Step c): Preparation of 3-amino-5-cyclobutyl-1H-pyrrolo[3,4-c]pyridine-1,6(5H)-dione
[0229] Methyl 5-cyano-1-cyclobutyl-2-oxo-1,2-dihydropyridine-4-carboxylate (2.4 g, 10.345 mmol) and methanolic ammonia (25 mL) were added to a sealed tube and stirred at room temperature overnight. The reaction solution was filtered and the filter cake dried to obtain 3-amino-5-cyclobutyl-1H-pyrrolo[3,4-c]pyridine-1,6(5H)-dione with a yield of 97.9%; ESI-MS (m / z): 218.0 [M+H] + .
[0230] Step d): Preparation of (R)-5-cyclobutyl-3-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1H-pyrrolo[3,4-c]pyridine-1,6(5H)-dione
[0231] (R)-5-Cyclobutyl-3-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1H-pyrrolo[3,4-c]pyridine-1,6(5H)-dione (800 mg, 3.687 mmol), (R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethane-1-amine hydrochloride (912 mg, 4.055 mmol) and ethanol (30 mL) were added to the reaction flask and the temperature was raised to 80 °C for 16 h. After the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 97 / 3) to obtain (R)-5-cyclobutyl-3-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1H-pyrrolo[3,4-c]pyridine-1,6(5H)-dione in a yield of 56.5%; ESI-MS (m / z): 390.0 [M+H] + .
[0232] Step e): Preparation of (R)-5-cyclobutyl-3-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1H-pyrrolo[3,4-c]pyridine-1,6(5H)-dione
[0233] (R)-5-cyclobutyl-3-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1H-pyrrolo[3,4-c]pyridine-1,6(5H)-dione (810 mg, 2.082 mmol) and ethanol (20 mL) were added to a reaction flask. Hydrazine hydrate (260 mg, 4.165 mmol, 80%) was added dropwise at 0°C. After the addition was complete, the reaction was continued at 0°C for 2 h. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 97 / 3) to obtain (R)-5-cyclobutyl-3-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1H-pyrrolo[3,4-c]pyridine-1,6(5H)-dione in a yield of 38.0%; ESI-MS (m / z): 405.2 [M+H] + .
[0234] Step f): (R)-1-chloro-6-cyclobutyl-4-(1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)pyrido[3,4-d]pyridazin-7(6H)-one
[0235] (R)-5-cyclobutyl-3-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1H-pyrrolo[3,4-c]pyridine-1,6(5H)-dione (320 mg, 0.792 mmol), DIPEA (153 mg, 1.188 mmol), phosphorus oxychloride (364 mg, 2.376 mmol) and acetonitrile (50 mL) were added to a reaction flask, and the temperature was raised to 105 ° C under nitrogen protection for 2 h. The reaction solution was cooled to room temperature and quenched with saturated aqueous sodium bicarbonate solution (50 mL). The mixture was extracted with dichloromethane (50 mL × 3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 4 / 1) to obtain (R)-1-chloro-6-cyclobutyl-4-(1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 43.4%; ESI-MS (m / z): 423.0 [M+H] + .
[0236] Step g): Preparation of (R)-6-cyclobutyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one
[0237] (R)-1-chloro-6-cyclobutyl-4-(1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)pyrido[3,4-d]pyridazin-7(6H)-one (50 mg, 0.118 mmol), N-methylpiperazine (24 mg, 0.237 mmol), and 1,4-dioxane (2 mL) were added to a reaction flask and heated to 120°C in a microwave oven for 1 hour. After completion of the reaction, the mixture was concentrated under reduced pressure, and the residue was purified by Prep-HPLC (Separation Method 3) to obtain (R)-6-cyclobutyl-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-1-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one in an 18.0% yield. 1H NMR (400MHz, DMSO-d6) δ9.07(s,1H),7.63(t,J=7.2Hz,2H),7.49(t,J=7.2Hz,1H),7.28(t,J=7.6Hz,1H),7.24(t,J=52.0Hz,1H),6.41(s,1H),5.65-5 .56(m,1H),5.22-5.11(m,1H),3.07-2.89(m,4H),2.49-2.41(m,8H),2.22( s,3H),1.93-1.83(m,2H),1.56(d,J=7.2Hz,3H); ESI-MS(m / z): 487.0[M+H] + .
[0238] With reference to the preparation method of Example 88, the compounds in the following examples were prepared using corresponding starting materials.
[0239] Example 209
[0240] Preparation of (R)-4-((1-(3-((difluoromethyl)sulfonyl)-2-methylphenyl)ethyl)amino)-6-(1-methylcyclopropyl)-1-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one
[0241] Step a): Preparation of (R)-1-chloro-4-((1-(3-((difluoromethyl)sulfonyl)-2-methylphenyl)ethyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one
[0242] 1,4-Dichloro-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one (50 mg, 0.185 mmol), (R)-1-(3-((difluoromethyl)sulfonyl)-2-methylphenyl)ethane-1-amine hydrochloride (58 mg, 0.204 mmol), N,N-diisopropylethylamine (72 mg, 0.555 mmol) and dimethyl sulfoxide (5 mL) were added to the reaction flask, the temperature was raised to 120°C, and the reaction was carried out for 1.5 h. After completion of the reaction, the reaction mixture was cooled to room temperature and quenched with saturated aqueous ammonium chloride solution (50 mL). The mixture was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1:3) to obtain (R)-1-chloro-4-((1-(3-((difluoromethyl)sulfonyl)-2-methylphenyl)ethyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one; yield: 67.2%; ESI-MS (m / z): 483.1 [M+H] +
[0243] Step b): Preparation of (R)-4-((1-(3-((difluoromethyl)sulfonyl)-2-methylphenyl)ethyl)amino)-6-(1-methylcyclopropyl)-1-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one
[0244] (R)-1-chloro-4-((1-(3-((difluoromethyl)sulfonyl)-2-methylphenyl)ethyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one (60 mg, 0.124 mmol), N-methylpiperazine (62 mg, 0.620 mmol), and 1,4-dioxane (2 mL) were added to a microwave tube and heated to 110°C in a microwave reactor for 1 hour. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by Prep-HPLC (Separation Method 3) to obtain (R)-4-((1-(3-((difluoromethyl)sulfonyl)-2-methylphenyl)ethyl)amino)-6-(1-methylcyclopropyl)-1-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 30.9%. 1H NMR(400MHz, DMSO-d6)δ9.21(s,1H),7.96(d,J=7.6Hz,1H),7.89(d,J=8.0Hz,1H), 7.62(d,J=6.8Hz,1H),7.54(t,J=8.0Hz,1H),7.34(t,J=52.0Hz,1H),6.38(s,1H),5 .57(p,J=6.8Hz,1H),3.08-2.88(m,4H),2.76(s,3H),2.49-2.37(m,4H),2.22(s,3H ),1.54(s,3H),1.50(d,J=6.9Hz,3H),1.20-1.03(m,4H); ESI-MS(m / z):547.2[M+H] + .
[0245] Referring to the preparation method of Example 209, the compounds in the following examples were prepared with corresponding starting materials.
[0246] Biological activity test
[0247] Test Example 1: SOS1 inhibitory activity assay
[0248] The effect of SOS1 inhibitors on the interaction between SOS1 and KRAS proteins was detected by homogeneous time-resolved fluorescence (HTRF) to evaluate the inhibitory level of SOS1 protein. The protein and detection reagent used were KRAS-G12D / SOS1 BINDING ASSAY KIT (Cisbio). First, the 2mM test compound stock solution was diluted 20 times (100μM) with Diluent reagent, and then the concentration was diluted 5 times in succession with Diluent reagent (5% DMSO) to obtain a total of 8 concentrations of the test compound working solution. In a 384-well plate, 4μL tag2-KRAS was added to each well. G12D Protein (containing 50 μM GTP), 2 μL test compound, 4 μL tag1-SOS1 protein, duplicate wells, incubate at room temperature for 15 minutes. Anti-tag1-Tb 3+ 5 μL each of the working solution and Anti-tag2-XL665 working solution were incubated at 4°C for 3 h. The 384-well plate was placed on a multifunctional microplate reader and read. The excitation wavelength was set to 337 nm, and the readings at 620 nm and 665 nm were recorded. The data were presented as the ratio of the 665 nm signal value to the 620 nm signal value for each well, i.e., Ratio = 104 ×665nm signal value / 620nm signal value. Calculate the inhibition rate by the Ratio value:
[0249] IC 50 The inhibition rate was calculated by GraphPad Prism software. Two replicate wells were tested for each compound. IC 50 The value is 1.4 to 100.0 nM. The test data of some example compounds are shown in Table 1:
[0250] Table 1 Inhibitory activity of some of the compounds in the examples on SOS1
[0251] It can be seen that the compounds of the present invention have strong SOS1 inhibitory activity, and compared with the corresponding SOS1 inhibitory activity data in Table 1 of PCT / CN2023 / 104412, the compounds of the present invention introduce -NR at the R4 position. 11 R 12 Compared with other types of substituents such as cycloalkyl and cycloalkenyl groups, the functional group has significantly enhanced inhibitory activity against SOS1.
[0252] Test Example 2: Determination of the inhibitory activity on NCI-H358 cell proliferation
[0253] Comparative Compound 1
[0254] The synthesis method is as follows:
[0255] Step a): Preparation of dimethyl 2-formyl-3-oxoglutarate
[0256] Dimethyl 3-oxoglutarate (10.0 g, 57.421 mmol) and 1-methyltetrahydrofuran (100 mL) were added to a reaction flask. DMF-DMA (6.8 g, 57.42 mmol) was added dropwise under an ice-water bath and the reaction was stirred at room temperature for 2 h. 4N dilute hydrochloric acid (30 mL) was added to the reaction solution and the reaction was continued at room temperature for 1 h. After the reaction, the reaction solution was extracted with methyl tert-butyl ether (100 mL). The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain dimethyl 2-formyl-3-oxoglutarate, which was used directly in the next reaction without further purification in a yield of 98.6%; ESI-MS (m / z): 203.2 [M+H]+ .
[0257] Step b): Preparation of methyl 4-hydroxy-1-(1-methylcyclopropyl)-6-oxo-1,6-dihydropyridine-3-carboxylate
[0258] Dissolve 1-methylcyclopropane-1-amine hydrochloride (4.7 g, 43.925 mmol) and dimethyl 2-formyl-3-oxoglutarate (8.9 g, 43.925 mmol) in methanol (120 mL), add sodium methoxide (5.2 g, 96.635 mmol) under ice-water bath, and heat to 80°C for 6 h. After the reaction, the reaction solution was cooled to room temperature and concentrated under reduced pressure to remove most of the solvent. A saturated aqueous ammonium chloride solution (100 mL) was added to quench the reaction. The reaction solution was adjusted to pH 2-3 with 4N hydrochloric acid to precipitate a large amount of solid. The solid was filtered and the filter cake was washed with 1N dilute hydrochloric acid. The filter cake was collected and dried under reduced pressure. The filter cake was slurried with a mixed solvent of methyl tert-butyl ether and petroleum ether (80 mL, v / v=4 / 1), filtered, and the filter cake was dried under reduced pressure to obtain methyl 4-hydroxy-1-(1-methylcyclopropyl)-6-oxo-1,6-dihydropyridine-3-carboxylate in a yield of 83.8%; ESI-MS (m / z): 224.2 [M+H] + .
[0259] Step c): Preparation of methyl 1-(1-methylcyclopropyl)-6-oxo-4-(trifluoromethyl)sulfonyl)oxy)-1,6-dihydropyridine-3-carboxylate
[0260] Methyl 4-hydroxy-1-(1-methylcyclopropyl)-6-oxo-1,6-dihydropyridine-3-carboxylate (6.4 g, 28.662 mmol), pyridine (4.5 g, 57.324 mmol) and 1,2-dichloroethane (60 mL) were added to the reaction flask, and trifluoromethanesulfonic anhydride (12.1 g, 42.993 mmol) was added under ice-water bath, and the reaction was stirred under ice-water bath for 2 min. The reaction was quenched by adding saturated aqueous ammonium chloride (50 mL). The mixture was allowed to stand and separate. The aqueous phase was extracted with dichloromethane (100 mL). The combined organic phases were washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1 to 3 / 1) to give methyl 1-(1-methylcyclopropyl)-6-oxo-4-(trifluoromethyl)sulfonyl)oxy)-1,6-dihydropyridine-3-carboxylate in a yield of 91.2%; ESI-MS (m / z): 356.2 [M+H] + .
[0261] Step d): Preparation of methyl 4-acetyl-1-(1-methylcyclopropyl)-6-oxyl-1,6-dihydropyridine-3-carboxylate
[0262] 1-(1-methylcyclopropyl)-6-oxo-4-(trifluoromethyl)sulfonyl)oxy)-1,6-dihydropyridine-3-carboxylic acid methyl ester (9.0 g, 25.352 mmol), 1,4-dioxane (60 mL), tributyl(1-ethoxyvinyl)tin (11.9 g, 32.958 mmol), triethylamine (3.3 g, 32.958 mmol) and bis(triphenylphosphine)palladium dichloride (356 mg, 0.507 mmol) were added to the reaction flask in sequence, the atmosphere was replaced with nitrogen three times, the temperature was raised to 100 ° C and the reaction was stirred overnight. After the reaction, the reaction solution was cooled to room temperature, the solvent was evaporated under reduced pressure, 4N dilute hydrochloric acid was added to adjust the pH to 2-3, and stirring was continued at room temperature for 1 hour. Saturated potassium fluoride aqueous solution (80 mL) was added to quench the reaction, ethyl acetate (100 mL) was added, and stirring was continued for 30 minutes. The reaction mixture was filtered, and the filter cake was washed with ethyl acetate (50 mL). The filtrate was separated, and the organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1) to obtain methyl 4-acetyl-1-(1-methylcyclopropyl)-6-oxy-1,6-dihydropyridine-3-carboxylate in a yield of 83.3%; ESI-MS (m / z): 250.2 [M+H] + .
[0263] Step e): Preparation of 4-hydroxy-1-methyl-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one
[0264] Methyl 4-acetyl-1-(1-methylcyclopropyl)-6-oxyl-1,6-dihydropyridine-3-carboxylate (5.0 g, 20.059 mmol) and anhydrous ethanol (50 mL) were added to a reaction flask. Hydrazine hydrate (5 mL, 80%) was added at room temperature and stirred at 80°C for 1 h. The reaction solution was cooled to room temperature and concentrated under reduced pressure. Ethyl acetate (30 mL) was added to the residue and the mixture was stirred at room temperature for 1 h. The mixture was filtered and the filter cake was rinsed with ethyl acetate (30 mL). The filter cake was collected and dried under reduced pressure to obtain 4-hydroxy-1-methyl-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 95.6%. ESI-MS (m / z): 232.1 [M+H] + .
[0265] Step f): Preparation of 4-bromo-1-methyl-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one
[0266] 4-Hydroxy-1-methyl-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one (950 mg, 4.108 mmol), phosphorus oxybromide (2.4 g, 8.720 mmol), and acetonitrile (100 mL) were added to a reaction flask and heated to reflux for 2 h. The reaction solution was cooled to room temperature and quenched with saturated sodium bicarbonate aqueous solution (200 mL). The mixture was extracted with dichloromethane (200 mL x 2). The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 4-bromo-1-methyl-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one in an 82.7% yield. ESI-MS (m / z): 294.0 [M+H] + .
[0267] Step g): Preparation of (R)-1-methyl-4-((1-(2-methyl-3-(trifluoromethyl)phenyl)ethyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one
[0268] 4-Bromo-1-methyl-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one (100 mg, 0.340 mmol), (R)-1-(2-methyl-3-(trifluoromethyl)phenyl)ethan-1-amine hydrochloride (160 mg, 0.668 mmol), DIPEA (260 mg, 2.012 mmol), cesium fluoride (310 mg, 2.041 mmol) and DMSO (3 mL) were added to a reaction flask and the temperature was raised to 80°C for 3 h. After the reaction was complete, the mixture was cooled to room temperature and quenched with saturated aqueous ammonium chloride (40 mL). The mixture was extracted with dichloromethane (40 mL × 2). The organic phases were combined, washed with saturated brine (30 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica gel column chromatography (eluent: methanol / dichloromethane = 5 / 95) and then purified by Prep-HPLC (separation method 3) to obtain (R)-1-methyl-4-((1-(2-methyl-3-(trifluoromethyl)phenyl)ethyl)amino)-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one in a yield of 14.3%. 1HNMR (400MHz, DMSO-d6) δ9.24(s,1H),7.76(d,J=6.8Hz,1H),7.73(d,J=7.6Hz,1H),7.54(d,J=7.6Hz,1H),7.35(t,J=7.6Hz,1H),6.46 (s,1H),5.64-5.54(m,1H),2.53(s,3H),2.32(s,3H),1.54(s,3H),1.51(d,J=7.2Hz,3H),1.20-1.04(m,4H); ESI-MS(m / z): 417.0[M+H] + .
[0269] Comparative Compound 2
[0270] The synthesis method is as follows:
[0271] 4-Bromo-1-methyl-6-(1-methylcyclopropyl)pyrido[3,4-d]pyridazin-7(6H)-one (450 mg, 1.530 mmol), (R)-1-(3-(trifluoromethyl)phenyl)ethane-1-amine hydrochloride (690 mg, 3.058 mmol), DIPEA (1.2 g, 9.285 mmol), cesium fluoride (0.9 g, 5.925 mmol) and DMSO (10 mL) were added to a reaction flask and the temperature was raised to 80 °C for 3 h. After the reaction, the mixture was cooled to room temperature and quenched by adding saturated aqueous ammonium chloride solution (40 mL). The mixture was extracted with dichloromethane (50 mL × 2). The organic phases were combined, washed with saturated brine (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by Prep-HPLC (separation method 1) to obtain (R)-1-methyl-6-(1-methylcyclopropyl)-4-((1-(3-(trifluoromethyl)phenyl)ethyl)amino)pyrido[3,4-d]pyridazin-7(6H)-one hydrochloride in a yield of 12.8%. 1 H NMR(400MHz,DMSO-d6)δ13.33(s,1H),10.63(s,1H),10.16(s,1H),8.00-7.97(m,2H),7.69-7.62(m,2H),6.81(s,1H),5.53-5 .46(m,1H),2.42(s,3H),1.77(d,J=6.4Hz,3H),1.55(s,3H),1.28-1.18(m,2H),1.12-1.06(m,2H); ESI-MS(m / z): 403.2[M+H] + .
[0272] by CellTiter-Glo The reagent is used to detect the number of living cells, thereby evaluating the inhibitory effect of the compound on cell proliferation. Non-small cell lung cancer cells NCI-H358 (Nanjing Kebai) in the exponential growth phase were digested with trypsin-EDTA and seeded into 96-well ultra-low adsorption microplates, 100 μL per well, a density of 2000 cells / well, and cultured overnight at 37°C and 5% CO2 to form microspheres. The test compound was diluted 5 times with DMSO to obtain 8 concentrations of gradient dilutions, and then diluted with RPMI-1640 (10% FBS) cell culture medium to obtain the compound working solution (2×), which was added to the cell supernatant at 100 μL per well and continued to be cultured for 7 days at 37°C and 5% CO2. Remove the well plate and add 100 μL CellTiter-Glo After lysing for 10-30 minutes at room temperature, 70 μL of the lysate was aspirated and transferred to a white opaque 384-well plate. The 384-well plate was placed on a multifunctional microplate reader to record the luminescence value (RLU).
[0273] The inhibition rate was calculated by the following formula: Inhibition rate (%) = {[(RLU 阴性对照 -RLU 空白 )-(RLU 受试化合物 -RLU 空白 )] / (RLU 阴性对照 -RLU 空白 )}×100%
[0274] Note: Negative control refers to the group without inhibitor, and blank refers to the group without cells.
[0275] IC 50 The inhibition rate was calculated by GraphPad Prism software. IC 50 The values are 9.6-65.3 nM. The inhibitory activities of some example compounds and comparative compounds on NCI-H358 cell proliferation are shown in Table 2.
[0276] Table 2 Inhibitory activity of some compounds in the examples on NCI-H358 cell proliferation
[0277] From the data in Table 2, it can be seen that the compounds of the present invention have significantly improved anti-tumor activity compared with comparative compound 1 and comparative compound 2. 11 R 12 Compared with R4 being other types of substituents such as methyl, the anti-tumor activity is significantly enhanced.
[0278] Test Example 3: Determination of metabolic stability of liver microsomes
[0279] Metabolic stability influences a compound's clearance rate, half-life, and oral bioavailability, and is one of its most important ADME (Adverse Reactions, Metabolism, and Metabolism) properties. Liver microsomal stability assays are a common method for studying metabolic stability. This study employed rat liver microsomal assays to investigate the metabolic stability of compounds.
[0280] Test methods
[0281] a. Solution preparation:
[0282] Preparation of compound stock solution: Take appropriate amount of test compound and testosterone, prepare into 1 mM stock solution with DMSO, and store in a refrigerator at 4°C.
[0283] Preparation of compound working solution: Take 1 mM compound stock solution and then use acetonitrile-water (v:v=1:1)
[0284] Dilute to 100 μM.
[0285] Preparation of NADPH working solution: Weigh an appropriate amount of NADPH and use 16mM MgCl2 to prepare a 4.0mM NADPH working solution.
[0286] Preparation of rat liver microsome working solution: Take an appropriate amount of rat liver microsomes and dilute them with PBS to make 1 mg / ml liver microsome working solution.
[0287] b. Sample incubation:
[0288] To the incubation system, 48 μL of PBS, 100 μL of rat liver microsome working solution, and 2 μL of the test compound working solution were added sequentially and mixed thoroughly. After preincubation at 37°C for 5 minutes, 50 μL of NADPH was added to initiate the reaction. After incubation for the appropriate time point, the reaction was terminated by adding an appropriate amount of glacial acetonitrile containing an internal standard. The mixture was vortexed and centrifuged, and the supernatant was collected and injected into LC-MS / MS to determine the residual amount of the compound metabolites.
[0289] c. Data processing:
[0290] Use Excel or other software to process the data according to the following formula. CL (liver) =(CL int(liver) ×f u ×Q h ) / (CL int(liver) ×f u +Q h )
[0291] Default f u (free fraction in blood) is equal to 1.
[0292] The stability test results of the compounds in some examples and the reference compound MRTX0902 on rat liver microsomes are shown in Table 3:
[0293] Table 3 Rat liver microsome stability test results
[0294] MRTX0902 is a compound disclosed in WO2021127429 (Examples 12-10), which has been reported to have SOS1 inhibitory activity and has entered Phase I clinical trials. As shown in Table 3, the compound of the present invention has better metabolic stability and better drugability than MRTX0902.
[0295] In addition, compared with the corresponding rat liver microsome stability test data in Table 2 of PCT / CN2023 / 104412, it can be seen that the compound of the present invention introduces -NR 11 R 12 Compared with R4 being other types of substituents such as methyl, hydroxyl, etc., the metabolic stability is significantly improved.
[0296] Test Example 4: Determination of liver drug metabolizing enzyme inhibitory activity
[0297] The liver is the primary site of drug metabolism, and the primary component of the mixed-function oxidase system present in the liver is the CYP450 enzyme. This enzyme system causes the majority of clinical drug interactions, leading to an increased incidence of adverse drug reactions. CYP450 is a large supergene family composed of numerous isoenzymes, of which CYP3A4, as the primary metabolizing enzyme, is involved in the metabolism of nearly half of all drugs used clinically. Similarly, CYP2C9 and CYP2C19 are also important metabolizing enzymes, clinically involved in the metabolism of a wide range of drugs. Therefore, early testing of compounds for their inhibitory activity against CYP450 enzymes can assess the risk of drug-drug interactions and improve medication safety.
[0298] In the present invention, human liver microsomes were used as the CYPP450 enzyme source, and specific probe substrates for each CYP isoform (where CYP3A4 used two substrates, midazolam and testosterone, represented by CYP3A4-M and CYP3A4-T, respectively) were incubated with a series of concentrations of the test compound in the presence of the cofactor NADPH. LC-MS / MS was used to measure the amount of metabolites produced by the probe substrate in the incubation system, and the IC values of the test compound for each CYP450 enzyme isoform were calculated. 50The inhibitory effect on each CYP450 enzyme subtype was evaluated by measuring the IC value. During the experiment, 49 μL PBS, 50 μL probe substrate, and 50 μL human liver microsome working solution were added to the incubation system in sequence, and then 1 μL of each concentration of the test compound working solution was added and mixed evenly; after pre-incubation at 37°C for 5 minutes, 50 μL NADPH was added to start the reaction. After incubation for the corresponding time, an appropriate amount of glacial acetonitrile containing the internal standard was added to terminate the reaction, vortexed to mix, centrifuged to obtain the supernatant, and injected into LC-MS / MS to detect the amount of metabolites produced by the probe substrate. The enzyme activity at the 0 concentration point (characterized by the amount of metabolite produced) was taken as 100%, and the percentage of residual enzyme activity of the metabolite at different test compound concentrations was calculated. IC 50 The residual enzyme activity was calculated using Graphpad Prism software.
[0299] The experimental results show that the inhibitory activity of the compounds of the present invention against CYP2C9, CYP2C19, CYP3A4-M, and CYP3A4-T is significantly weaker than that of the reference compound MRTX0902, which helps reduce the risk of drug-drug interactions. For example, Table 4 below lists the test data of some of the example compounds of the present invention and the reference compound MRTX0902:
[0300] Table 4 Drug metabolizing enzyme inhibition activity test data
[0301] From the data in Table 4, it can be seen that the compound of the present invention has a weaker inhibitory effect on liver drug metabolizing enzymes than the compound MRTX0902 and has better drug-forming properties.
[0302] In addition, compared with the corresponding liver drug metabolizing enzyme inhibition activity test data in Table 4 of PCT / CN2023 / 104412, it can be seen that the compound of the present invention introduces -NR 11 R 12 Compared with other types of substituents such as methyl, the inhibitory effect of R4 on CYP2C9 is significantly weakened.
[0303] Test Example 5: Pharmacokinetics test in rats
[0304] Male Sprague-Dawley rats weighing 200-250 g were divided into two groups, three in each, with IV and PO administration. The IV group received 1 mg / kg of the test compound by intravenous injection, while the PO group received 5 mg / kg by oral gavage. Whole blood was collected before IV administration and at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after administration; and before PO administration and at 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after administration. The blood was collected in K2-EDTA anticoagulant tubes, centrifuged within 30 minutes at 4°C, and plasma was separated and stored at -80°C until analysis. Samples were processed for protein precipitation using an appropriate amount of acetonitrile containing an internal standard, vortexed, and centrifuged. The supernatant was then sampled for LC-MS / MS analysis. Based on the measured plasma concentrations, key pharmacokinetic parameters were calculated and the pharmacokinetic behavior was evaluated. The main pharmacokinetic parameters were analyzed using the non-compartmental model using WinNonLin 8.3 software.
[0305] Pharmacokinetic studies in rats showed that the oral bioavailability of the compound of the present invention reached 100%-110% when administered orally to rats. This compares to 22.6% for the reference compound MRTX0902. Compared to MRTX0902, the oral bioavailability of the compound of the present invention was significantly improved.
[0306] Test Example 6: Pharmacokinetic Study in Mice
[0307] Female Balb / c mice, weighing 19-21 g, were divided into two groups, each consisting of 9 mice in the IV and PO groups (cross-sampling). The IV group received 1 mg / kg of the test compound via intravenous injection, while the PO group received 10 mg / kg via oral gavage. Whole blood was collected before IV administration and at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after administration; and before PO administration and at 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after administration. Blood was collected in K2-EDTA tubes, centrifuged at 4°C for 30 minutes, and plasma was separated and stored at -80°C until analysis. Samples were precipitated with an appropriate amount of acetonitrile containing an internal standard, vortexed, and centrifuged. The supernatant was then sampled for LC-MS / MS analysis. Based on the measured plasma concentrations, key pharmacokinetic parameters were calculated and pharmacokinetic behavior was evaluated. The main pharmacokinetic parameters were analyzed using the non-compartmental model using WinNonLin 8.3 software.
[0308] Pharmacokinetic studies in mice showed that the oral bioavailability of the compound of the present invention reached 100%-110% when administered orally to mice. This compares to 40.4% for the reference compound MRTX0902. Compared to MRTX0902, the oral bioavailability of the compound of the present invention was significantly improved.
[0309] Test Example 7: Beagle dog pharmacokinetic study
[0310] Male beagle dogs weighing 9-12 kg were divided into two groups, three in each of the IV and PO groups, based on similar weight. The IV group received 1 mg / kg of the test compound by intravenous injection, while the PO group received 5 mg / kg by oral gavage. Whole blood was collected before IV administration and at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after administration; and before PO administration and at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after administration. The blood was collected in K2-EDTA anticoagulant tubes, and plasma was separated by centrifugation (4°C) within 30 minutes and stored at -80°C until analysis. Samples were processed for protein precipitation using an appropriate amount of acetonitrile containing an internal standard, vortexed, and centrifuged. The supernatant was then sampled for LC-MS / MS analysis. Based on the measured plasma concentrations, key pharmacokinetic parameters were calculated and the pharmacokinetic behavior was evaluated. The main pharmacokinetic parameters were analyzed using the non-compartmental model using WinNonLin 8.3 software.
[0311] The results of the beagle dog pharmacokinetic test showed that when the compound of the present invention was administered to the beagle dogs via oral gavage, the oral bioavailability could reach 100%-110%, indicating high oral bioavailability.
[0312] Test Example 8: In vivo efficacy test
[0313] This study used a subcutaneous xenograft tumor model of human pancreatic cancer MIA PaCa-2 cells to evaluate the antitumor activity of the compounds of the present invention. Female Balb / c-nu nude mice, 6-8 weeks old, weighing approximately 18-22 grams, were selected for the experiment. 5×10 6 MIA PaCa-2 cells (suspended in 0.10 mL of 50% Matrigel suspension). 3 At 14:00, group dosing began. The test compound of the present invention was administered orally (PO) twice a day (BID). Tumor volume and body weight were measured twice a week. Tumor volume was measured in cubic millimeters and calculated using the following formula: V = 0.5a × b 2, where a and b are the long and short diameters of the tumor, respectively. The anti-tumor efficacy of the test compound was evaluated using the tumor growth inhibition rate (TGI) (%). TGI (%) was calculated as follows: TGI (%) = [1 - (average tumor volume at the end of dosing in a given treatment group - average tumor volume at the start of dosing in that treatment group) / (average tumor volume at the end of dosing in the solvent control group - average tumor volume at the start of dosing in the solvent control group)] × 100%. Body weight change (%) was calculated as follows: Body weight change (%) = (average weight of animals in a given treatment group at the end of dosing - average weight of animals in that treatment group at the start of dosing) / average weight of animals in that treatment group at the start of dosing × 100%.
[0314] The experimental results showed that the compound of the present invention had a TGI (%) in the range of 45% to 90%, and had good anti-tumor activity. The animals did not show a significant decrease in body weight and had good tolerance.
[0315] Based on the above experimental results, it can be seen that the compounds of the present invention have a significant inhibitory effect on SOS1 and can be used as SOS1 inhibitors, with broad application prospects in fields such as cancer and pathogenic eczema mediated by the SOS1 protein. In addition, compared with MRTX0902, the compounds of the present invention have better metabolic stability in liver microsomes, weaker inhibitory effects on liver drug-metabolizing enzymes, and higher oral bioavailability, indicating excellent drugability and clinical application prospects.
[0316] While embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions, and variations may be made to these embodiments without departing from the principles and spirit of the invention, and that the scope of the invention is defined by the appended claims and their equivalents.
Claims
1. A compound of formula I, or a tautomer, stereoisomer, solvate, metabolite, isotope-labeled substance, pharmaceutically acceptable salt, or cocrystal thereof: in: Ring A is selected from aryl, heteroaryl, wherein the aryl, heteroaryl is optionally selected from halogen, alkyl, alkoxy, -OH, -CN, -NR5R6, -SF5, -SO2R 10 The alkyl and alkoxy groups may be further substituted by substituents selected from halogen, -NR5R6, and -OH, wherein R5 and R6 are independently selected from H, alkyl, and R 10 is an alkyl group and is optionally substituted by halogen; or, two substituents on the aryl group or heteroaryl group are connected to form an aliphatic carbocyclic ring, and the aliphatic carbocyclic ring is optionally substituted by halogen; R a , R b , R c Independently selected from H, alkyl; R1 and R3 are independently selected from H, halogen, alkyl, alkoxy, -OH, -CN, -NR7R8, and the alkyl and alkoxy groups are optionally substituted by substituents selected from halogen and -NR7R8, wherein R7 and R8 are independently selected from H and alkyl; R2 is selected from H, alkyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, wherein the cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl is optionally selected from halogen, alkyl, alkoxy, -C(=O)R9 is substituted by a substituent, R9 is selected from alkyl, cycloalkyl, heterocycloalkyl; R4 is -NR 11 R 12 , R 11 , R 12 are independently selected from H, alkyl, cycloalkyl, heterocycloalkyl, wherein when R 11 and / or R 12 When alkyl, the alkyl may be selected from -OH, alkenyl, halogen, -NR 14 R 15 , substituted by a cycloalkyl substituent, R 14 , R 15 independently selected from H, alkyl; when R 11 and / or R 12 When selected from cycloalkyl and heterocycloalkyl, the cycloalkyl and heterocycloalkyl may be optionally substituted by alkyl; or R 11 , R 12 and the N atom connected thereto together form a heterocycloalkyl group, wherein the heterocycloalkyl group can be optionally selected from halogen, alkyl, cycloalkyl, -C(=O)R 13 , The alkyl group may be substituted by a substituent selected from -OH, cycloalkyl, etc., wherein R 13 is an alkyl group; or R 11 , R 12 Together with the nitrogen atom to which it is attached, it forms a heteroaryl group.
2. The compound according to claim 1, characterized in that Ring A is selected from aryl, heteroaryl, wherein the aryl, heteroaryl is optionally selected from halogen, alkyl, alkoxy, -OH, -CN, -NR5R6, -SF5, -SO2R 10 The alkyl and alkoxy groups may be further substituted by substituents selected from halogen and -NR5R6, wherein R5 and R6 are independently selected from H, alkyl, R 10 is alkyl and is optionally substituted by halogen.
3. The compound according to claim 1 or 2, characterized in that Ring A is selected from 6- to 12-membered aryl groups and 5- to 12-membered heteroaryl groups, wherein the heteroaryl group contains a heteroatom selected from N, O, and S, and the substituents of the above groups are as defined in claim 1 or 2; Preferably, ring A is phenyl, and its substituents are as defined in claim 1 or 2.
4. The compound according to any one of claims 1 to 3, characterized in that The substituent contained in ring A is selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, -OH, -CN, -NR5R6, -SF5, -SO2R 10 The alkyl and alkoxy groups may be further substituted by a substituent selected from halogen, -NR5R6, and -OH, wherein R5 and R6 are independently selected from H, C1-C6 alkyl, and R 10 is a C1-C6 alkyl group and is optionally substituted by halogen; or, two substituents on ring A are connected to form a 5-6 membered aliphatic carbocyclic ring, and the aliphatic carbocyclic ring is optionally substituted by halogen; Preferably, the substituent contained in ring A is selected from halogen, C1-C6 alkyl, -CN, -NR5R6, -SF5, -SO2R 10 , the alkyl group may be further substituted by a substituent selected from halogen, -OH, wherein R5 and R6 are independently selected from H, C1-C6 alkyl, R 10 is a C1-C6 alkyl group and is optionally substituted by halogen; or, two substituents on ring A are connected to form a 5-6 membered aliphatic carbocyclic ring, and the aliphatic carbocyclic ring is optionally substituted by halogen; Preferably, the substituent contained in ring A is selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, -OH, -CN, -NR5R6, -SF5, -SO2R 10 The alkyl and alkoxy groups may be further substituted by a substituent selected from halogen and -NR5R6, wherein R5 and R6 are independently selected from H, C1-C6 alkyl, and R 10 is C1-C6 alkyl and is optionally substituted by halogen; Preferably, the substituent contained in ring A is selected from halogen, C1-C6 alkyl, -CN, -NR5R6, the alkyl is optionally further substituted by halogen, and R5 and R6 are independently selected from H, C1-C6 alkyl; Preferably, the substituent contained in ring A is selected from -F, -CH3, -CHF2, -CF3, -CN, -NH2, -SF5, -SO2CHF2, -CF2CH2OH; or, two substituents on ring A are connected to form Wherein both ends of a and b are connected to two adjacent ring carbon atoms on ring A respectively; Preferably, the substituent contained in ring A is selected from -F, -CH3, -CHF2, -CF3, -CN, and -NH2.
5. The compound according to any one of claims 1 to 4, characterized in that Ring A is selected from: Preferably, ring A is selected from:
6. The compound according to any one of claims 1 to 5, characterized in that R a , R b , R c Independently selected from H, C1-C6 alkyl; Preferably, R a , R b , R c Independently selected from H, methyl; Preferably, R a is methyl, R b For H, R c For H.
7. The compound according to any one of claims 1 to 6, characterized in that The structure is shown in Formula II: wherein each group is as defined in any one of claims 1 to 5.
8. The compound according to any one of claims 1 to 7, characterized in that R1 and R3 are independently selected from H, halogen, C1-C6 alkyl, C1-C6 alkoxy, -OH, -CN, -NR7R8, and the alkyl and alkoxy groups are optionally substituted with substituents selected from halogen and -NR7R8, wherein R7 and R8 are independently selected from H and C1-C6 alkyl.
9. The compound according to any one of claims 1 to 7, characterized in that R1 and R3 are independently selected from H, alkyl, alkoxy, -OH, -CN, -NR7R8, and the alkyl and alkoxy groups are optionally substituted by substituents selected from halogen and -NR7R8, wherein R7 and R8 are independently selected from H and alkyl; Preferably, R1 and R3 are independently selected from H, C1-C6 alkyl, C1-C6 alkoxy, -OH, -CN, -NR7R8, and the alkyl and alkoxy groups are optionally substituted by substituents selected from halogen and -NR7R8, wherein R7 and R8 are independently selected from H, C1-C6 alkyl; Preferably, R1 and R3 are both H.
10. The compound according to any one of claims 1 to 9, characterized in that R2 is selected from H, C1-C6 alkyl, 3-10-membered cycloalkyl, 3-10-membered heterocycloalkyl, 3-10-membered cycloalkenyl, 3-10-membered heterocycloalkenyl, wherein the cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl may be selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, -C(=O)R9 is substituted by a substituent, R9 is selected from C1-C6 alkyl, 3-10-membered cycloalkyl, 3-10-membered heterocycloalkyl, and the heterocycloalkyl and heterocycloalkenyl groups contain heteroatoms selected from N, O, and S; Preferably, R2 is selected from H, C1-C6 alkyl, 3-10-membered cycloalkyl, 3-10-membered heterocycloalkyl, 3-10-membered heterocycloalkenyl, and the cycloalkyl, heterocycloalkyl, and heterocycloalkenyl groups are optionally substituted by substituents selected from C1-C6 alkyl, C1-C6 alkoxy, and -C(=O)R9, and R9 is selected from C1-C6 alkyl, 3-10-membered heterocycloalkyl, and the heterocycloalkyl and heterocycloalkenyl groups contain 1-2 heteroatoms selected from N, O, and S; Preferably, R2 is selected from H, C1-C6 alkyl, 3-membered cycloalkyl, 5-6-membered heterocycloalkyl, 6-membered heterocycloalkenyl, the cycloalkyl, heterocycloalkyl, heterocycloalkenyl may be optionally substituted by a substituent selected from C1-C6 alkyl, C1-C6 alkoxy, -C(=O)R9, R9 is selected from C1-C6 alkyl, 6-membered heterocycloalkyl, the heterocycloalkyl, heterocycloalkenyl contains 1-2 heteroatoms selected from N, O; Preferably, R2 is selected from C1-C6 alkyl, 3-8 membered cycloalkyl, 5-8 membered heterocycloalkyl, the cycloalkyl and heterocycloalkyl are optionally substituted by substituents selected from halogen and C1-C6 alkyl, and the heterocycloalkyl contains 1-2 heteroatoms selected from N and O; Preferably, R2 is a C1-C6 alkyl group; or, R2 is selected from cyclopropane, cyclobutane, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, 3-azabicyclo[3.3.0]octanyl, and the above groups are optionally substituted by substituents selected from halogen and C1-C6 alkyl; Preferably, R2 is a cyclopropane group, which is optionally substituted by a C1-C6 alkyl group; Preferably, R2 is selected from: methyl, ethyl, Preferably, R2 is selected from:
11. The compound according to any one of claims 1 to 10, characterized in that R4 is -NR 11 R 12 , where R 11 , R 12 is independently selected from H, alkyl, cycloalkyl, the alkyl is optionally substituted by a substituent selected from -OH, alkenyl, the cycloalkyl is optionally substituted by an alkyl; or, R 11 , R 12 and the N atom connected thereto together form a heterocycloalkyl group, wherein the heterocycloalkyl group can be optionally selected from halogen, alkyl, cycloalkyl, -C(=O)R 13 , Substituents, R 13 is an alkyl group; or, R 11 , R 12 Together with the nitrogen atom to which it is attached, it forms a heteroaryl group.
12. The compound according to any one of claims 1 to 11, characterized in that R4 is -NR 11 R 12 , R 11 , R 12 are independently selected from H, C1-C6 alkyl, 3-10-membered cycloalkyl, 3-10-membered heterocycloalkyl, wherein the heterocycloalkyl contains a heteroatom selected from N, O, and S; wherein R 11 and / or R 12 When it is C1-C6 alkyl, the alkyl group may be selected from halogen, -NR 14 R 15 , substituted by a 3- to 10-membered cycloalkyl substituent, R 14 , R 15 independently selected from H, C1-C6 alkyl; when R 11 and / or R 12 When selected from 3- to 10-membered cycloalkyl and 3- to 10-membered heterocycloalkyl, the cycloalkyl and heterocycloalkyl may be optionally substituted by C1-C6 alkyl; Preferably, R4 is -NR 11 R 12 , R 11 , R 12 are independently selected from H, C1-C6 alkyl, 3-8-membered cycloalkyl, 4-8-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1-2 heteroatoms selected from N and O; wherein R 11 and / or R 12 When it is C1-C6 alkyl, the alkyl group may be selected from halogen, -NR 14 R 15 , substituted by a 3- to 8-membered cycloalkyl substituent, R 14 , R 15 independently selected from H, C1-C6 alkyl; when R 11 and / or R 12 When selected from 3- to 8-membered cycloalkyl and 4- to 8-membered heterocycloalkyl, the cycloalkyl and heterocycloalkyl may be optionally substituted by C1-C6 alkyl; Preferably, R4 is -NR 11 R 12 , where R 11 , R 12 Independently selected from H, C1-C6 alkyl, 3-10-membered cycloalkyl, the C1-C6 alkyl is optionally substituted by a substituent selected from -OH, C2-C6 alkenyl, the 3-10-membered cycloalkyl is optionally substituted by a C1-C6 alkyl; Preferably, R4 is -NR 11 R 12 , where R 11 , R 12 Independently selected from H, C1-C6 alkyl, 3-5 membered cycloalkyl, the C1-C6 alkyl is optionally substituted by a substituent selected from -OH, C2-C6 alkenyl, the 3-5 membered cycloalkyl is optionally substituted by a C1-C6 alkyl; Preferably, R4 is -NR 11 R 12 , R 11 , R 12 are independently selected from H, C1-C6 alkyl, cyclopropane, bicyclo[1.1.1]pentane, oxetanyl, tetrahydropyrrolyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, 1-azabicyclo[2.2.2]octanyl; wherein, when R 11 and / or R 12 When it is C1-C6 alkyl, the alkyl group may be selected from halogen, -NR 14 R 15 , substituted by a 3-membered cycloalkyl substituent, R 14 , R 15 independently selected from H, C1-C6 alkyl; when R 11 and / or R 12 When selected from cyclopropane, bicyclo[1.1.1]pentane, oxetanyl, tetrahydropyrrolyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, 1-azabicyclo[2.2.2]octanyl, the above groups may be optionally substituted by C1-C6 alkyl; Preferably, R4 is -NR 11 R 12 , where R 11 , R 12 Independently selected from H, methyl, ethyl, propyl, cyclopropane, wherein the cyclopropane is optionally substituted with methyl; Preferably, R4 is selected from: Preferably, R4 is selected from: Preferably, R4 is 13. The compound according to any one of claims 1 to 11, characterized in that R4 is -NR 11 R 12 , R 11 , R 12 and the N atom connected thereto together form a 3-10 membered heterocycloalkyl, wherein the heterocycloalkyl contains a heteroatom selected from N, O, and S, and the heterocycloalkyl can be optionally selected from halogen, C1-C6 alkyl, 3-10 membered cycloalkyl, -C(=O)R 13 , The alkyl group may be substituted by a substituent selected from -OH, a 3- to 10-membered cycloalkyl group, wherein R 13 is a C1-C6 alkyl group; Preferably, R4 is -NR 11 R 12 , where R 11 , R 12 and the N atom connected thereto together form a 3-10 membered heterocycloalkyl, wherein the heterocycloalkyl contains a heteroatom selected from N, O, and S, and the heterocycloalkyl can be optionally selected from halogen, C1-C6 alkyl, 3-10 membered cycloalkyl, -C(=O)R 13 , Substituents, R 13 is a C1-C6 alkyl group; Preferably, R4 is -NR 11 R 12 , R 11 , R 12 and the N atom connected thereto together form a 4-10 membered heterocycloalkyl group, wherein the heterocycloalkyl group contains 1-2 heteroatoms selected from N, O, and S, and the heterocycloalkyl group can be optionally selected from halogen, C1-C6 alkyl, 3-5 membered cycloalkyl, -C(=O)R 13 , The alkyl group may be substituted by a substituent selected from -OH, a 3- to 5-membered cycloalkyl group, wherein R 13 is a C1-C6 alkyl group; Preferably, R4 is -NR 11 R 12 , where R 11 , R 12 and the N atom connected thereto together form a 4-6 membered heterocycloalkyl group, wherein the heterocycloalkyl group contains 1-2 heteroatoms selected from N, O, and S, and the heterocycloalkyl group can be optionally selected from halogen, C1-C6 alkyl, -C(=O)R 13 , Substituents, R 13 is a C1-C6 alkyl group; Preferably, R4 is -NR 11 R 12 , R 11 , R 12 Together with the N atoms connected to it, The above groups can be optionally selected from halogen, C1-C6 alkyl, 3-5 membered cycloalkyl, -C(=O)R 13 , The alkyl group may be substituted by a substituent selected from -OH, a 3- to 5-membered cycloalkyl group, wherein R 13 is a C1-C6 alkyl group; Preferably, R4 is -NR 11 R 12 , where R 11 , R 12 and the N atom connected thereto together form an azetidinyl, a tetrahydropyrrolyl, a tetrahydrothiazolyl, a piperidinyl, a piperazinyl, a morpholinyl, a thiomorpholinyl, a 3-azabicyclo[3.1.0]hexyl group, wherein the above group can be optionally selected from fluorine, methyl, -C(=O)R 13 , Substituents, R 13 is methyl; Preferably, R4 is -NR 11 R 12 , where R 11 , R 12 Together with the N atom connected thereto, it forms an azetidinyl group or a piperazinyl group, wherein the above group can be optionally selected from fluorine, methyl, -C(=O)R 13 , Substituents, R 13 is methyl; Preferably, R4 is selected from: Preferably, the configuration of R4 is selected from at least one of the following: Preferably, R4 is selected from: Preferably, for 14. The compound according to any one of claims 1 to 11, characterized in that R4 is -NR 11 R 12 , where R 11 , R 12 Together with the N atom connected thereto, it forms a 5-10-membered heteroaryl group, wherein the heteroaryl group contains a heteroatom selected from N, O, and S; Preferably, R4 is -NR 11 R 12 , where R 11 , R 12 Together with the N atom connected thereto, it forms a 5-membered heteroaryl group, wherein the heteroaryl group contains 1 to 3 N heteroatoms; Preferably, R4 is -NR 11 R 12 , where R 11 , R 12 Together with the N atom connected thereto, it forms pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl; Preferably, R4 is selected from:
15. The compound according to any one of claims 1 to 14, characterized in that Select one of the following:
16. A pharmaceutical composition, characterized in that A compound comprising any one of claims 1 to 15, or its tautomer, stereoisomer, solvate, metabolite, isotope-labeled product, pharmaceutically acceptable salt, cocrystal, and pharmaceutically acceptable excipients or auxiliary ingredients.
17. Use of the compound according to any one of claims 1 to 15, or its tautomer, stereoisomer, solvate, metabolite, isotope-labeled product, pharmaceutically acceptable salt, cocrystal, or the pharmaceutical composition according to claim 16 in the preparation of an SOS1 inhibitor.
18. Use of the compound according to any one of claims 1 to 15, or its tautomer, stereoisomer, solvate, metabolite, isotope-labeled product, pharmaceutically acceptable salt, cocrystal, or the pharmaceutical composition according to claim 16 in the preparation of a medicament for treating a disease mediated by SOS1.
19. The use according to claim 18, characterized in that: The disease is selected from the group consisting of cancer and pathogenic rash diseases.
20. The use according to claim 19, characterized in that: The cancer is selected from the group consisting of non-small cell lung cancer, lung cancer, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, chronic myeloid leukemia, colorectal cancer, brain cancer, liver cancer, kidney cancer, stomach cancer, and breast cancer; The pathogenic rash disease is selected from: Noonan syndrome, cardiofacial cutaneous syndrome, and hereditary gingival fibromatosis type I.
21. Use of the compound according to any one of claims 1 to 15, or its tautomer, stereoisomer, solvate, metabolite, isotope-labeled product, pharmaceutically acceptable salt, cocrystal, or the pharmaceutical composition according to claim 16 in the preparation of a medicament for treating a disease causing overexpression of SOS1 protein.
22. Use of the compound according to any one of claims 1 to 15, or its tautomer, stereoisomer, solvate, metabolite, isotope-labeled product, pharmaceutically acceptable salt, cocrystal, or the pharmaceutical composition according to claim 16 in the preparation of a medicament for treating a disease caused by overexpression of SOS1 protein.
Citation Information
Patent Citations
Novel benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
US20190358230A1
2-methyl-AZA-quinazolines
WO2019201848A1
SOS1 inhibitors
WO2021127429A1
Pyridazopyridone derivative and use thereof
WO2024002318A1
SOS1 inhibitors
CN115135315A
Cited By
Salt form of pyridazine derivative, crystal form, method for preparing same, and use thereof
WO2026108837A1
